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SUPPORTED LIQUID EXTRACTION 
 
DANIEL LEE 
 
ABSTRACT 
 
Synthetic cannabinoids have become a growing concern in society. The extensive 
list of synthetic cannabinoids and the abuse rate has drawn the attention by government 
agencies throughout the world. These synthetic cannabinoids can adopt a number of 
different structures, while still acting on endogenous cannabinoid (CB1 and CB2) 
receptors. In addition, due to structural modifications of these synthetic cannabinoids, 
many of these compounds can bind to CB1 and CB2 receptors with greater affinity causing 
severe adverse and life-threatening effects. Because of their structural dissimilarity to 
the phytocannabinoid Δ9-THC, combating the rapid growth and emergence of synthetic 
cannabinoids with conventional THC-based methods has become an ongoing struggle.  
            The purpose of this research was to develop and validate a robust and reliable 
method to accurately identify and quantify 17 synthetic cannabinoids in human whole 
blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The method 
was validated in accordance to SWGTOX guidelines for quantitative analysis using the 
following analytes: 4-cyano-CUMYL-BUTINACA, 5F-3,5-ABPFUPPYCA, 5F-ADB-
PINACA, 5F- PY-PINACA, ADB-PINACA, APP-PICA, CUMYL-THPINACA, EMB-
FUNICACA, JWH-250, MDMB-FUBICA, MEP-CHMICA, MO-CHMINACA, 
NM2201, PB-22, RCS-8, UR144, and XLR11. 
 vi 
             With this developed method, total analysis time was 8 minutes with samples 
eluting from 3.8 to 5.8 minutes. Calibration curves for each analyte had acceptable 
R2 values > 0.98 using a weighting factor of 1/x. A linear dynamic range of 0.5 – 25 ng/mL 
was used for all analytes, except for APP-PICA, XLR11 and NM2201 which were 
quantifiable at 0.1 ng/mL and PB-22 which used a quadratic model.  Extraction of analytes 
using supported liquid extraction (SLE) cartridge improved sample-prep time by more than 
half, compared to traditional solid phase extraction (SPE) methods. Percent recovery of 
analytes using SLE was determined to be from 54.92 to 83.36%. Bias and Precision was 
assessed at 1, 3, 7, and 20 ng/mL for all analytes. All samples had acceptable calculated 
percent bias and percent coefficient of variation (%CV) within ±20%. No carryover was 
observed with this method. Matrix effect, using 10 different sources, did not have any 
interfering effects on detection and quantification of analytes. Ionization suppression and 
enhancement was observed at various levels, from -4.47 to 76.67%, but had little effect on 
other validation parameters. Analysis of other commonly encountered drugs (clonazepam, 
diazepam, (+) methadone, morphine, fentanyl, cocaine, amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA), 25I-NBOMe, and phencyclidine 
(PCP)) does not show any source of interference.   
            The overall development and validation of this method demonstrates a sensitive 
and reliable way to positively identify 17 different synthetic cannabinoids in human whole 
blood in rapid time. 
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1. Introduction 
 
1.1 Background and Chemistry 
 
Cannabinoids have been one of the oldest and longest abused substances in our 
society. Prior to the Controlled Substances Act of 1970, cannabis has been used for 
thousands of years to treat medical ailments.1 There are currently 29 states that have 
adopted its legal medical applications.2 Today, there are numerous applications for medical 
marijuana. Medical marijuana is currently used to help nausea and vomiting in 
chemotherapy patients, increase appetite or used for analgesic effects for acquired immune 
deficiency syndrome (AIDS) patients and patients with multiple sclerosis experiencing 
mild to moderate pain.3,4 With the increasing demand for medical applications of cannabis 
and to better understand endogenous cannabinoid receptors came the emergence of 
synthetic cannabinoids.5,6,7 
There are other potential research areas for medical marijuana including 
bronchodilation from asthma, reduction of intraocular pressure in glaucoma patients, or 
potentially used as anticonvulsants, anxiolytic, analgesic, or anti-inflammatory agents.4 
Synthetic cannabinoids are a class of synthetic compounds known to produce marijuana-
like effects by acting on endogenous cannabinoid CB1 and CB2 receptors, hence are 
known to have cannabimimetic properties.8 Unlike most other novel psychoactive 
substances (NPS) that are analogs or isomeric forms of their natural-producing counterpart, 
synthetic cannabinoids may take on a completely different structure compared to the 
phytocannabinoid molecule, tetrahydrocannabinol (Δ9-THC).9,10 It is important to note that 
synthetic cannabinoids can act on receptors producing cannabinoid effects (full agonist) 
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but there is a class of synthetic cannabinoids that can also act as antagonists; blocking 
receptor-activity without any cannabimimetic effects.11 For the purposes of this transcript, 
we will focus primarily on synthetic cannabinoids known to have agonistic properties.  
 
1.2 Recreational Use 
1.2.1 Synthetic Cannabinoids as Designer Drugs 
Designer drugs, also known as NPS, have been synthesized to provide a desired 
physiological and psychological effects, often similar to that of a federally controlled 
substance.12,13 NPS compounds are sought out from users as an alternative method for 
recreational use without the fear of legal repercussions. Like some NPS, newly emerging 
synthetic cannabinoids are not currently scheduled under the Controlled Substances Act 
(CSA); therefore they are marketed as a ‘legal highs.’12 There are also many classes of 
synthetic cannabinoids that are structurally dissimilar to the phytocannabinoid Δ9-THC 
which is how these NPS are able to circumvent current drug tests.9 In addition, due to their 
full agonistic effects, synthetic cannabinoids have greater potency compared to Δ9-THC, 
which poses another issue of low doses and concentrations in the body, making 
toxicological analysis difficult.  
 
1.2.2 History and Scheduling 
Δ9-THC, the major psychoactive ingredient, was discovered and isolated in the 
plant species Cannabis sativa in 1960’s.12,14 In 1970, cannabis was placed on the CSA as 
a Schedule I drug, restricting its recreational and legal applications.15 Although cannabis 
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was federally scheduled, many states approved its legal applications of medical marijuana. 
In the Late 1970’s approximately 24 states approved legislation (The Controlled 
Substances Therapeutic Research Act) to circumvent the federal regulations set forth by 
the Controlled Substances Act of 1970.16 In the 1980s, a synthetic cannabinoid 
(dronabinol) was approved by the Food & Drug Administration (FDA) to treat nausea and 
vomiting for chemotherapy patients.4 A Belgian company, Solvay Pharmaceuticals began 
distributing and marketing the synthetic cannabinoid dronabinol under the trademark, 
Marinol.4  
Soon after the emergence of dronabinol, researchers began synthesizing 
cannabinoids to better understand endogenous cannabinoid receptors.5,6 One of the earliest 
synthesized cannabinoids was HU-210, which was synthesized in 1988 by Raphael 
Mechoulam from Hebrew University (HU-compounds).12,17 John W. Huffman, a professor 
from Clemson University is also prized with synthesizing hundreds of synthetic 
cannabinoids commonly known as JWH-compounds.6 Others include Pfizer who 
synthesized the cyclohexylphenol series (CP-compounds) and Alexandros Markriyannis 
who synthesized the AM-compounds.18,19 
In the early 2000’s, synthetic cannabinoids began being sold and distributed online 
in European countries, marketed under the name ‘Spice’ (also known as K2) in specialized 
smoke-shops (headshops) and online markets.20 Prior to government scrutiny, these Spice-
products were readily available online, being sold without any age restrictions, and sold as 
‘legal highs’ or ‘herbal highs’.12,21 Of the earliest known emergence of Spice (K2) was sold 
in 2004, predominantly in European countries. By 2008, synthetic cannabinoids gained 
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enormous popularity in many European countries (Austria, Germany, France, Poland and 
Sweden).12 In that same year, two major compounds synthetic cannabinoids (CP-47,497 
and JWH-018) were identified as the psychoactive ingredient in Spice (K2) products.22,23  
In early 2009, high abuse rate of Spice (K2) products gained the attention of the 
European Monitoring Centre for Drugs and Drug Addiction’s (EMCDDA) early warning 
system on newly emerging drugs.24 Shortly after the early detection of synthetic 
cannabinoids, growing concerns from the Advisory Council on the Misuse of Drugs 
(ACMD)25 forced the European government to make amendments to the Misuse of Drugs 
Act 1971 where they classified synthetic cannabinoids as a controlled substance in the 
United Kingdom (U.K.).26 These compounds or any Spice-related products were restricted 
by the European government and no longer accessible through headshops and online-
markets.12 However, the recent amendments did not deter clandestine laboratories from 
manufacturing and distributing; instead, various other synthetic cannabinoids not yet 
classified have been substituted in Spice products. In 2009 the synthetic cannabinoid HU-
210 was identified.27 In 2010, JWH-015 was identified in a spice-related product called 
‘Topaz’ along with other newly emerged derivative compounds, JWH-122, which was a 
methyl-derivative of JWH-018.28   
As synthetic cannabinoids grew in popularity, spice-related products eventually 
made its way into the United States (U.S.) in 2008; advertised online as ‘K2’ and other 
various names (e.g. Spice, Spice Gold, Spice Diamond, Dream, Silver, and Genie).11,29 The 
first known appearance of synthetic cannabinoids in the U.S. was in Dayton, Ohio.30 in late 
2008, U.S. Customs and Border Protection noticed large shipments of Spice (K2) products 
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being shipped into the USA.29 The increasing popularity of synthetic cannabinoids in the 
U.S. raised concerns in various states including Alabama, Arkansas, Georgia, Kansas, 
Kentucky, and Missouri. In November 2010, the U.S. Drug Enforcement Administration 
(DEA) temporarily placed five synthetic cannabinoids (JWH-018, JWH-073, JWH-200, 
CP-47,497 and CP-47,497 C8 homologues) as Schedule I substances; and permanently 
scheduled in 2011.31 By 2011, Spice (K2)-related products have been reported all around 
the world; predominantly in the UK, USA, Germany, Japan, Austria, Ireland and Latvia).32 
Due to a plethora of different synthetic cannabinoids, once a cannabinoid 
compound is scheduled, a different synthetic cannabinoid can easily replace the recently 
scheduled compound. This endless cycle of newly emerging synthetic cannabinoids is a 
growing concern for the community and local law enforcements. 
 
1.2.3 Marketing, Use and Distribution 
Synthetic cannabinoids are produced in laboratories and are dissolved in a solvent, 
which can then be sprayed onto non-psychoactive plant-matter, dried and packaged for 
distribution.12,33  Most typical plant materials used in with synthetic cannabinoids are 
Damiana (Turnera diffusa), Marshmallow (Althaea officinalis), Mugwort (Artemisia 
vulgaris) or Mullein (Verbascum thapsus).34 Spice (K2) has also been sold in powder or 
liquid forms.35 In both Europe and U.S., a typical 3-gram dried plant material typically 
costs €20–€30 Euros, and $30–$40 U.S. Dollars (USD), respectively.36 The dried leaf 
products sprayed with synthetic cannabinoids can eventually be smoked using a pipe or 
rolled with cigarette paper.37,36 In a worldwide survey conducted by Vandrey et al. 
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including 13 countries and 42 U.S. States, majority of self-administered individuals 
favored the smoking routes of administration (via pipe, bong and cigarette paper) but also 
included oral, rectal, and vaporized via e-cigarette routes of administration.38 
What first started out as ‘Legal Highs,’ easily accessible without any age 
restrictions with specific labels ‘K2’ or ‘Spice’ soon turned into something much more 
dangerous.12,21 Due to government scrutiny and scheduling of the first five synthetic 
cannabinoids (JWH-073, JWH-200, CP-47,497 and CP-47,497-C8 homologue),39 many 
headshops and online-markets began advertising and packaging spice-related products 
under different names such as ‘Insense,’ ‘fragrance’ and ‘potpourri’ with additional 
warning labels, ‘not for human consumption’ in order to circumvent legal regulations and 
detection.4,36 These Spice (K2) products with mis-labelled packaging, without any 
indication of type active-ingredients,36 cause users to speculate the actual concentration of 
Spice (K2) products; often taking more than a person should consume. In 2011, the 
National Institute on Drug Abuse (NIDA) reports indicated that synthetic cannabinoids 
were second highest abused substance, just after cannabis.40 
The growing use of Spice (K2) increased at an alarming rate. According to the 
National Poison Data System from the American Association of Poison Control Centers’ 
(AAPCC), in 2009 there were 112 calls of exposure to Spice (K2). The number of callers 
increased to 2,915 in 2010,41 11,561 calls in 2012,42 32,653 in 2013, 33,653 in 2014, and 
29,588 in 2015.43 
The other concern is also the target consumers. Due to its easy accessibility, Spice 
(K2) products are used amongst the youth in the U.S.36 A survey conducted in 2011 from 
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hundreds of high schools nationwide showed approximately 11.4% of 12th grade seniors, 
8.8% of 10th graders, and 4.4% of 8th graders admitted to using synthetic cannabinoids.44 
Although the recreational use of synthetic cannabinoids has subsided in recent years, the 
National Forensic Laboratory Information System (NFLIS) annual reports indicate that two 
synthetic cannabinoid  (XLR11 and AB-CHMINACA) are among the top 25 substances 
that are still currently being abused throughout the U.S.45 
The most concerning aspect of recreational use of Spice (K2) products are the 
potential active ingredients. It has been reported that Spice-products may not only contain 
synthetic cannabinoids as its primary active ingredient, but may also contain other NPSs 
(e.g. synthetic opioids).46 Other concerns of Spice products include hypnotic-inducing 
ingredients, or even a combination of numerous synthetic cannabinoids present in a single 
Spice product.47,48 The active ingredients found in Spice products can vary greatly 
depending on the country of origin.12 The ambiguity of listed active ingredients or lack-
there-of in Spice (K2) products is another concern for the general public. 
 
1.3 Chemical structure 
1.3.1 Structure of Synthetic Cannabinoids 
There are seven major structural groups that synthetic cannabinoids can be classified 
under. Napthoylindoles (e.g. JWH-018), Napthylmethylindoles, Naphthopyrroles, 
Naphthylmethylindenes, Phenylacetylindoles (e.g. JWH-250), Cyclohexylphenols (e.g. 
CP47,497), and Classical cannabinoids (e.g. HU-210).49 The commonly abused synthetic 
cannabinoids, found in Spice (K2)-products can be classified into four major categories 
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known as Classical cannabinoids (e.g. HU-210), cyclohexylphenols (e.g. CP-47,497), 
phenylacetylindoles (e.g. JWH-250) , and naphthoylindoles (e.g. JWH-018).9,10 The 
structures of these four major categories are shown in Figure 1.  
 
 
 
 
 
 
 
 
1) Classical Cannabinoid (HU-210)  2) Cyclohexylphenol (CP-47,497) 
 
 
 
 
 
 
 
 
 
 
 
 
 
3) Phenylacetylindoles (JWH-250)  4) Napthoylindoles (JWH-018) 
 
 
 
Figure 1. Major Structures. Four commonly abused synthetic cannabinoid core structures 
are 1) classical cannabinoids, 2) cyclohexylphenols, 3) phenylacetylindoles, and 4) 
naphthoylindoles. 
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1.4 Cannabinoid Receptors (CB1 and CB2) 
1.4.1 Properties of CB1 and CB2 Receptors 
The earliest known discovery of cannabinoid (CB1) receptors was in 1984 by 
Howlett et al. demonstrating that cannabinoid activity decreased cyclic adenosine 
monophosphate (cAMP) concentrations in the brain, primarily in the neuroblastoma cells.50 
CB1 receptors have been determined to be a part of the rhodopsin-family of G-protein-
coupled receptors (GPCR).51 GPCR’s, in general, are characterized by a transmembrane-
unit with alpha helices coupled with several G-proteins (Gα, Gβ and Gγ), which produces 
a cascade effects upon activation by a protein ligand.52 The initial discovery of CB 
receptors were later confirmed in rat brain in 1988 and successfully cloned from rat tissues 
in 1990.53 The discovery of CB1 receptors allowed researchers to understand the 
pharmacological effects of cannabinoid agonists; the CB1 activity in the basal ganglia and 
cerebellum have been proven to be associated with the person’s gait, and activity in the 
cerebral cortex and hippocampus have been proven to be associated with effects on 
cognition and memory.54 
Upon studying the CB1 receptors further, came the discovery of CB2 receptors. In 
1993, studying the immunomodulatory effects of cannabis enabled researchers to identify 
and isolate a second class of cannabinoid receptors, the CB2 receptor.55 Although, CB1 
and CB2 receptors share nearly half of its protein sequence, CB1 receptors have been 
isolated predominantly in the central nervous system (CNS) with minor peripheral nervous 
system (PNS)-activity.56,57 For many year, CB2 receptors have been known as PNS 
cannabinoid receptors due to its high spleen and immune cell activity and absence of 
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expression in the brain.58 It was later determined in 2005, that both CB1 and CB2 receptors 
are localized in both the CNS and PNS.59 At this point, there is now convincing evidence 
of two types of cannabinoid receptors, CB1 and CB2 receptors.  
 
1.5 Pharmacology of Synthetic Cannabinoids 
Although metabolic studies involving synthetic cannabinoids began in the early 2000’s, 
it was not studied in depth until 2010, when an alarming rate of exposures were reported 
by the AAPCC.60 However, due to the recent emergence, the diverse chemical compounds, 
and the rapid introduction of differing synthetic cannabinoids, pharmacological studies are 
limited to only a handful number of synthetic compounds. Of the several hundreds of 
different synthetic cannabinoids available, recent pharmacological studies include AB-001, 
AM694, AM2201, CP55,940, JWH-015, JWH-018, JWH-019, JWH-073, JWH-210, PB-
22,  RCS-8, UR-144, and XLR-11.61 Because there is currently no FDA approved studies, 
many pharmacology studies have been observed through animal studies, self-
experiments,61 clinical reports, and toxicological reports.   
 
1.5.1 Pharmacodynamics 
Pharmacodynamics is the study of a drugs particular mechanism of action and how 
it affects the body.62 As mentioned previously, synthetic cannabinoids have been known to 
have cannabimimetic effects by acting on the CB1 and CB2 receptors. Surprisingly, 
synthetic cannabinoids have been reported to act on CB1 and CB2 receptors as full agonists 
with greater affinity compared to the phytocannabinoid Δ9-THC.5 Many synthetic 
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cannabinoids have been synthesized over the years to fully understand cannabinoid 
receptors and to improve its medicinal applications.  
In 2016, Bow and Rimoldi helped shed some light on the structural relationship 
between synthetic cannabinoids and receptor activity. Although primarily focusing on the 
classical cannabinoid structure, Bow and Rimoldi demonstrate the affinity and selectivity 
on CB1 and CB2 receptors is directly correlated to the functional-group substitutions; for 
example, increasing C3 alkyl side-chains, substitution of C1 phenol groups, and 
modifications on C9/C11 groups can all impact the selectivity on cannabinoid receptors, 
sometimes having an upwards of 300-times selectivity; causing greater adverse effects.51 
To fully understand the structure-affinity of cannabinoids and receptor activity, there needs 
to be a larger focus which include other classes of synthetic cannabinoids (e.g. 
cyclohexylphenols, phenylacetylindoles, and naphthoylindoles).  
Many users seek recreational use of synthetic cannabinoids for its cannabis-like 
effects, which may include elevated mood and sense of wellbeing.12 Alarmingly, synthetic 
cannabinoids are known to be more potent than cannabis due to their full agonist 
properties.6 However, another reason may be due to the lack of cannabidiol (CBD) in 
synthetic cannabinoids. CBD is naturally produced in cannabis species, and may act as an 
antagonist of CB1 and CB2 receptor agonists.63 Unfortunately, there is not sufficient data 
in human trials and very few in animals to fully grasp the effects of synthetic cannabinoids. 
Many known side-effects are primarily known through case reports, clinical reports, or 
self-administered reports through online forums.12 Although synthetic cannabinoids are 
known to have cannabimimetic effects (e.g. euphoria and elevated mood), there are many 
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common adverse effects, which may be directly related to synthetic cannabinoid ingestion. 
The types of side-effects associated with synthetic cannabinoids can vary depending on the 
user or the type of Spice (K2) products used; nevertheless the list of potential effects is 
alarmingly extensive.12  
For acute exposures, synthetic cannabinoids can cause euphoric effects, feeling of 
well-being and relaxation with mild memory impairments. However, acute exposures can 
still have adverse effects, which may include neurological effects (i.e. dizziness, ataxia and 
nystamus), cardiovascular issues (e.g. chest pain, hypertension, palpitations) and 
gastrointestinal issues (e.g. nausea, vomiting).64 Acute users are also prone to psychotic 
reactions, although has not been consistently reported for every case.65 Chronic users are 
more likely to experience any number of these effects with greater risks. Of the most 
common symptoms observed from recreational users include nausea, anxiety, agitation, 
panic attacks, tachycardia, paranoia, and hallucinations.64 In addition, recent studies have 
demonstrated tolerance, withdrawal, and dependencies involved in chronic users.66,67 
Chronic users are also prone to lethal effects which may include seizures, coma, and 
suicidal thoughts.64,68  
 
1.5.2 Pharmacokinetics 
Pharmacokinetics is the study of a drug’s movement, interaction, and time-course 
within the body including its bioavailability, absorption, distribution, metabolism, and 
elimination.62 Due to lack of available resources and the large array of synthetic 
compounds, pharmacokinetic information is limited. However, general conclusions can be 
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drawn from synthetic cannabinoid metabolism. For example, synthetic cannabinoids have 
been seen to undergo extensive oxidation and conjugation metabolism.69 The sequence of 
forming metabolites for the process of elimination in the human body begins via oxidation 
by a superfamily of enzymes called cytochrome P450 (CYP450) which are typically 
associated with liver metabolism, which is then conjugated with glucuronic acid via UDP-
glucuronosyltransferases (UGTs).69  
With phytocannabinoids for example, metabolism of Δ9-THC is oxidized by 
cytochrome P-subtypes (e.g. CYP2C9 and CYP3A4), which forms the major psychoactive 
metabolite, 11-hydroxy- Δ9-THC and later excreted via conjugation.70 Similarly, synthetic 
cannabinoids metabolism also involves various CYP-subtypes.  CYP2C9 and CYP1A2 
have been isolated as the primary oxidative enzyme in the metabolism of JWH-018 and 
AM2201.71 Other CYP-subtypes have also been identified in a tissue specific manner. 
CYP2C9 is found high expressed in the intestine (for oral ingestion ROA) and CYP1A2 is 
found in the lungs (for smoking ROA). Although the liver is the primary role in drug and 
xenobiotic metabolism, it has been reported that the liver plays a minimal role in oxidative 
metabolism of synthetic cannabinoids.69 Although the pharmacology of many synthetic 
cannabinoid compounds are unanswered, a handful of known metabolic bio-
transformations include hydroxylation, carboxylation, dehydrogenation, N-dealkylation, 
dihydrodiol formation, ketone formation, O-demethylation, oxidative defluorination, and 
ring opening in phase I metabolism, and glucuronic acid conjugation in phase II 
metabolism.61 
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One of the major issues surrounding synthetic cannabinoids include low dosage and 
concentrations in the body. This is due to having a greater potency, which requires less 
amount of substance to achieve a “high”. In addition to the low dosage, the rapid 
metabolism of synthetic cannabinoids poses issues in toxicological analysis. Unlike Δ9-
THC, where parent compounds can be detected in plasma for up to 7 days and metabolites 
in urine for up to 12 days or longer in chronic users,72 synthetic cannabinoids have a shorter 
window of detection. Synthetic cannabinoids have been reported to decrease in 
concentration of parent compounds drastically in human serum within 21 hrs and 
approximately 3 days for metabolites.61 Because of this, detectability of synthetic 
cannabinoids is dependent on the amount of time that has elapsed since ingestion and time 
of bodily fluid collection.  
 
2. Current Detection Methods 
Due to structural dissimilarities of synthetic cannabinoids, conventional THC 
screening and confirmatory analysis are ineffective. Duquenois color test, a standard 
screening technique used to determine the presence of Δ9-THC has been practiced for many 
years.73 However, due to dissimilar functional groups of Δ9-THC and other synthetic 
cannabinoids, Duquenois color test cannot presumptively identify presence of these NPS 
compounds. Another screening technique was the presence of botanical features found on 
the plant Cannabis sativa L.; for example the presence of cystolith hairs, resin glands, 
glandular hairs and trichomes.4 GC-MS and LC-MS, the gold standards in toxicological 
analysis, may not always identify these synthetic compounds. Because of the structural 
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dissimilarities, without certified reference standards, positively identifying or reporting 
synthetic cannabinoids can be near impossible.  
In the past several years, certified reference standard suppliers have been 
manufacturing and supplying certified reference materials enabling laboratories to develop 
and validate analytical methods to positively identify the presence of synthetic 
cannabinoids in human bodily fluids. To-date, there are various analytical methods that 
have been developed: enzyme-linked immunosorbent assay (ELISA), gas 
chromatography–mass spectrometry (GC-MS), liquid chromatography–tandem mass 
spectrometry (LC-MS/MS), positive and negative ESI ionization LC-MS/MS, liquid 
chromatography–time-of-flight mass spectrometry (LC-TOF/MS), liquid 
chromatography–high resolution mass spectrometry (LC-HRMS), and homogenous 
EMIT-type assay (HEIA).61 In addition to various analytical and immunoassay techniques, 
various sample preparation techniques have been developed for the analysis of synthetic 
cannabinoids: hydrolysis, liquid-liquid extraction (LLE), solid-phase extraction (SPE), 
dilution, TMS-derivatization and –acylation, NaOH digestion, base hydrolysis, protein 
precipitation, salting-out liquid-liquid extraction and supported-liquid extraction (SLE).61  
 
3. Research Objective 
Recreational use of synthetic cannabinoids has become a global issue since 
2008.11,60 Although the Drug Enforcement Administration has had a positive impact on 
identifying illicit activities, clandestine laboratories are continuously modifying the 
structure of synthetic cannabinoids to circumvent legal regulations.45 The alarming rate at 
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which these synthetic cannabinoids are reaching the market has become a never-ending 
battle for forensic laboratories. Therefore, the goal of this research project is to provide the 
forensic community with a newly developed method for accurately and reliably identifying 
and quantifying commonly encountered synthetic cannabinoid compounds.  
Utilizing the sensitivity and resolving power of the liquid chromatography– tandem 
mass spectrometry, this method positively identified and quantified the presence of 4-
cyano CUMYL-BUTINACA, 5-fluoro-3,5-ABPFUPPYCA, 5-fluoro ADB-PINACA, 5-
fluoro PY-PINACA, ADB-PINACA, APP-PICA, CUMYL-THPINACA, EMB-
FUBINACA, JWH-250, MDMB-FUBICA, MEP-CHMICA, MO-CHMINACA, NM2201, 
PB-22, RCS-8, UR144, and XLR11. Figure 2 shows the structures the synthetic 
cannabinoids and Figure 3 shows the internal standards. Validation of this method was 
performed in accordance to the Scientific Working Group for Forensic Toxicology 
(SWGTOX) guidelines, which includes determining the limit of detection (LOD), limit of 
quantitation (LOQ), linearity, accuracy, precision, carryover, dilution integrity, matrix 
interference, internal standard interference, and ionization suppression and enhancement.74  
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4-Cyano CUMYL-BUTINACA        5F-3,5-AB-PFUPPYCA       5F-ADB-PINACA 
 
 
 
 
 
 
 
 
 
 
  
5F-PY-PINACA                  ADB-PINACA                APP-PICA                  CUMYL-THPINACA 
 
 
 
 
 
 
 
 
 
 
 
EMB-FUBINACA                   JWH-250          MDMB-FUBICA          MEP-CHMICA 
 
 
 
 
 
 
 
 
 
 
MO-CHMINACA         NM2201 
 
Figure 2. Chemical Structure of All Reference Standards. Chemical structure of 4-
cyano CUMYL-BUTINACA, 5-fluoro-3,5-AB-PFUPPYCA, 5-fluoro ADB-PINACA, 5-
fluoro PY-PINACA, ADB-PINACA, APP-PICA, CUMYL-THPINACA, EMB-
FUBINACA, JWH-250, MDMB-FUBICA, MEP-CHMICA, MO-CHMINACA, NM2201, 
PB-22, RCS-8, UR144, and XLR11.  
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Figure 2. Chemical Structure. (cont.) Chemical structure of 4-cyano CUMYL-
BUTINACA, 5-fluoro-3,5-AB-PFUPPYCA, 5-fluoro ADB-PINACA, 5-fluoro PY-
PINACA, ADB-PINACA, APP-PICA, CUMYL-THPINACA, EMB-FUBINACA, JWH-
250, MDMB-FUBICA, MEP-CHMICA, MO-CHMINACA, NM2201, PB-22, RCS-8, 
UR144, and XLR11.  
 
 
 
 
 
 
 
 
 
 
 
      UR144-d5      PB-22-d9          XLR-d5  
 
 
Figure 3. Chemical Structure for All Internal Standards. Chemical structures of all 
deuterated internal standards UR144-d5, PB-22-d9, and XLR11-d5. 
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4. Materials and Methods 
4.1 Theory of Instrumentation 
4.1.1 Liquid Chromatography 
Liquid chromatography (LC) is a technique commonly used to separate 
components in a mixture by exploiting their physical and chemical affinities for a solid 
stationary phase and a liquid mobile phase.75 The solid stationary phase, commonly 
referred to as the “LC column,” is a cylindrical tube where the separation of components 
occurs. The liquid mobile phase is typically an organic solvent, which is used to help carry 
the components through the LC column.75 Once a mixture of components is introduced 
into the column, the various components will separate as they travel through the column 
due to their intermolecular interactions (van der Waal forces, hydrogen bonding, or dipole-
dipole interactions) associated between the LC column and the mobile phase. Analyte 
components that have a higher affinity (greater attraction) to the stationary phase travel 
through the column longer than analytes with little affinity and vice versa for analytes with 
lower affinity to the LC column. These individual analytes are then measured by their 
retention time (tR), which is the amount of time it takes for each analyte to exit or eluted 
out from the column.62 
Liquid chromatography systems are comprised of various components: solvent 
reservoir to house the mobile phase(s), a degassing unit to remove any air bubbles or 
dissolved gasses from the mobile phase line, an auto-sampler for autonomous injections, 
an oven that houses the solid-phase column, and a detector used to measure the tR of eluting 
analytes.62 The varying components of the system include the mobile phase(s) and the LC 
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column.  Depending on the type of chemistry and the desired separation, different mobile 
phases are used (e.g. methanol, acetonitrile, water, and other buffers).75 In addition, a 
complementary LC column is used to achieve the desired separation of analytes. These 
columns can come in various forms (e.g. column dimensions, pore size, and particle shape 
and size).75 The detector located at the end of the LC column measures the tR in the form 
of a chromatograph; a plot of time versus intensity. With these underlying theories, the LC 
system is an effective analytical instrument that uses high pressure to carry the mobile 
phase through the solid stationary phase, resulting in a more efficient separation.62  
 
4.1.2 Mass Spectrometry 
Mass Spectrometry (MS) is an analytical technique used to elucidate the chemical 
structure of compounds by analyzing their mass to charge (m/z) ratio. The MS system 
consists of an ionization source used to fragment and charge ions, mass-analyzer used to 
separate fragmented ions, and a detector to measure the m/z ratio of the separated ions.76 
Of the many ionization sources currently available, the most conventional is the electron 
impact ionization source. This specific source produces a stream of high-energy directly 
on analytes as they enter the source through a high-pressure vacuum.76 The stream of high-
energy electrons causes the bonds to break in the molecule resulting in fragmentation of 
charged ions. These charged fragments enter the mass-analyzer and separated. As these 
separated charged ions exit the mass-analyzer, the detector analyzes them and the data is 
generated in the form of a mass spectrum (e.g. m/z vs. intensity). 
A tandem mass spectrometer (MS/MS), similarly to the MS, consists of an 
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ionization source, mass analyzer, and a detector, all of which is housed under high-pressure 
vacuum. Compared to an MS system, the difference lies in the mass analyzer for the 
MS/MS system. Of the many types of mass analyzers available, the most conventional is 
the quadrupole, which consists of three components: Q1 mass analyzer, Q2 collision cell, 
and Q3 a second mass analyzer.76 The MS/MS system offers a higher degree of 
discriminating power by producing two types of charged ions: precursor (parent) ions and 
product ions, unlike the MS system, which only produces only single ions. This is a result 
of fragmentation occurring twice in the MS/MS system.  
The first fragmentation of analytes occur at the source, typically in an electrospray 
ionization (ESI) source which produces precursor (parent) ions.76 These precursor ions 
enter the mass analyzer under a high-pressure vacuum. The mass analyzer consists of four 
separate rods or quadrupoles; two of which have applied direct current (DC) and the other 
two with applied radio frequency (RF). These rods alternate in DC and RF, which allows 
ions of specific m/z to separate. As these precursor ions exit the Q1, it undergoes second 
fragmentation in Q2, which produces product ions. These products are then funneled into 
the Q3 mass analyzer where a second series of separation occurs and measured by a 
detector in the form of a mass spectra.76 
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4.1.3 Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS) 
 
Mass spectrometers are typically coupled with chromatography instruments, which 
act as a detector for eluting compounds. In this case, the coupled instrument is commonly 
referred to as liquid chromatography – tandem mass spectrometry (LC-MS/MS).62 Here, a 
mixture of different analytes is injected into the LC system, in which a mobile phase is 
used to carry the analytes through the LC column. Each individual analyte is then separated 
based on their physical and chemical affinity to the LC column. A piece of peek tubing 
connects the end of the LC column to the ionization source of the MS system, allowing 
eluting analytes to enter directly into the MS source.  
Electrospray ionization (ESI) is a soft ionization technique typically used in tandem 
mass spectrometry to produce multiple charged fragmented ions.62 Because the eluting 
analytes exiting the LC column is still in solution form, a high voltage probe is used to 
evaporate the solution into a fine aerosol. This charged aerosol then enters a low pressure, 
high temperature vacuum chamber coupled with pure nitrogen gas to vaporize the eluent 
of any remaining mobile phase, leaving only the gas-phase ions to enter the mass 
spectrometer.62 The gas phase ions enter the MS system and are accelerated via a series of 
rods with alternating direct current and radio frequency which allow these ions to travel 
through the first mass analyzer, undergo fragmentation in the collision cell, and filter 
through the second mass analyzer to reach the detector.62 
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4.2 Materials 
4.2.1 Standards/Reagents 
Milli-Q water from an Ultrapure (type 1) water system from Millipore Sigma 
(Burlington, MA, USA) was used throughout this study. Optima grade methanol (MeOH), 
optima grade isopropanol, optima grade formic acid (FA), and optima grade acetonitrile 
(ACN), ACS certified hexane, optima grade ethyl acetate, and ammonium formate were 
purchased from Thermo Fisher Scientific (NY, USA). 4-cyano CUMYL-BUTINACA, 5-
fluoro-3,5-ABPFUPPYCA, 5-fluoro ADB-PINACA, 5-fluoro MDMB-PICA, 5-fluoro 
PB-22, 5-fluoro PY-PINACA, ADB-PINACA, APP-PICA, CUMYL-THPINACA, EMB-
FUNICACA, JWH-250, MDMB-FUBICA, MEP-CHMICA, MO-CHMINACA, NM2201, 
PB-22, RCS-8, UR144, XLR11, UR144-d5, PB-22-d9, and XLR11-d5 were all purchased 
from Cayman Chemical Company (Ann Arbor, MI, USA) as standards of 1 mg neat solids 
(prepared in 1 mL of methanol) or 1 mg/mL and 100 µg/mL DEA exempt preparations in 
either MeOH or ACN. Table 1 list the Cayman Chemical certified materials (CRM) and 
lot numbers. Certified drug-free human whole blood was purchased from UTAK 
Laboratories, Inc. (Valencia, CA) and Equitech-Bio Inc. (Kerrville, TX). The Oakton 700 
pH meter used throughout this project was purchased from Thermo Fisher Scientific (NY, 
USA).  
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Table 1. Lot numbers of CRM). All CRM were stored at -20oC. 
 
Product Company Lot Numbers 
4-cyano CUMYL-BUTINACA Cayman Chemical 0490444-17 
5F-3,5-AB-PFUPPYCA Cayman Chemical 0472185-17 
5F-ADB-PINACA Cayman Chemical 0485273-10 
5F-PY-PINACA Cayman Chemical 048712 
ADB-PINACA Cayman Chemical 0468161 
APP-PICA Cayman Chemical 0470126-13 
CUMYL-THPINACA Cayman Chemical 0467623-26 
EMB-FUBINACA Cayman Chemical 0473498-25 
JWH-250 Cayman Chemical 0509389-01 
MDMB-FUBICA Cayman Chemical 0488504-12 
MEP-CHMICA Cayman Chemical 0506714-4 
MO-CHMINACA Cayman Chemical 0465397-25 
NM2201 Cayman Chemical 0464900-37 
PB-22 Cayman Chemical 0504390 
RCS-8 Cayman Chemical 0491176-1 
UR144 Cayman Chemical 0499668 
XLR11 Cayman Chemical 0498175-1 
UR144-d5 Cayman Chemical 0516864-1 
PB-22-d9 Cayman Chemical 0516372-1 
XLR11-d5 Cayman Chemical 0513591-1 
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4.2.2 UFLC-ESI-MS/MS Instrument Hardware and Software 
All analyses were performed on a Shimadzu UFLC Chromatography System with 
LC-20AD model pumps and SIL-20AC model auto-sampler (Kyoto, Japan). The LC 
column was a XBridgeTM C18 3.5uM, 2.1x50mm column (Waters, Milford, MA, U.S.A.). 
Analytes were detected on a SCIEX 4000 QTRAP tandem mass spectrometer with a Turbo 
VTM ESI (Framingham, MA, U.S.A.). Data were collected using Analyst® (version 1.6.2) 
software and quantitation was performed with MultiQuantTM 3.0 (version 3.0.5373.0) 
software (SCIEX).  
  
4.3 Methods 
4.3.1 Compound/ Source Optimization 
Manual optimization was performed by directly infusing each analyte into the mass 
spectrometer and data was reviewed in real-time using Analyst® software. Each CRM 
including all internal standards were serially diluted to a final concentration of 100 ng/mL 
and 10 ng/mL in a mixture 50% LC-grade methanol and 50% millipore water with 0.1% 
formic acid. Starting with 10 ng/mL, each analyte was loaded in a clean syringe and all air 
bubbles were removed. The syringe was placed onto a syringe pump and connected directly 
to the MS/MS source via peek tubing.  The infusion was set at a flow rate of 10 uL/min 
with only the mass spectrometer hardware profile activated. 
In Analyst® software, under “Manual Tuning,” the “Q1 MS” scan type was selected 
under positive ionization mode to determine approximate ranges of expected molecular 
weight; a range of ±50 Da of the expected molecular weight for each analyte. Dwell time 
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was set to 1 second and the “MCA” box was checked. The scan was acquired for 10 
minutes. Intensities of each analyte were monitored with an expected intensity of 1e5 – 1e7. 
If the intensity of any analyte fell below 1e5, infusion was repeated with 100 ng/mL. Once 
an appropriate intensity was stable in the total ion chromatograph, the m/z value (in Da) of 
the precursor (Q1) mass was reported.  
Keeping the same analyte and infusion rate, the scan type was changed to “Product 
Ion MS2.” The “MCA” box remained checked, and the previously obtained Q1 mass was 
entered in the column “product of.” The Q3 mass scan ranges were set at 50 Da (start) to 
approximately 20 Da above the obtained Q1 mass (stop). The Dwell time was kept at 1 
second, and collision energy (CE) ramp was applied to help induce fragmentation of Q3 
product ions. The m/z values of the two most intense product ions in the extracted ion 
chromatograph, were recorded as Q3 (1) and Q3 (2).  
Declustering potential (DP) was optimized next. Changing scan type to “MRM,” 
masses of Q1 and Q3 were entered in the MRM table. “Declustering Potential” was 
selected and scans were set at 150 msec dwell time. The voltages of the greatest intensity 
were observed for both product ions and recorded. The CE and collision cell exit potential 
(CXP) for each product ion Q3 (1) and (2) were evaluated next. Keeping the MRM scan 
type, only one Q1/ Q3 ions were evaluated separately. The Q1/Q3 values and DP voltage 
were entered in the MRM table, dwell time remained at 150 msec. Entrance potential (EP) 
was set at 10, and CE ramp was applied. The average maximum voltage of three scans was 
recorded as the CE. This CE value was added into the information window and CXP) ramp 
was applied. The scan was acquired three times, and the average apex of the greatest 
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voltage was recorded as the CXP. The CE and CXP were determined for each Q3 (1) and 
(2) product ions. This compound optimization procedure for determining the Q1, Q3, DP, 
CE, and CXP was repeated for all analytes and internal standards.  
Source optimization was performed on all analytes to optimize the curtain gas, 
collision gas, ion spray voltage, temperature and ion sources 1 and 2. Each analyte was 
diluted to a final concentration of 100 ng/mL in optima-grade methanol and loaded into a 
1 mL syringe. The syringe was fastened onto a syringe pump at a pump flow rate of 10 
uL/min. The infusion of the syringe was connected to the MS ion source and attached to 
the output of the LC column via a T-tube adaptor peek tubing. The hardware profile in 
Analyst® software “LC/MS” was activated. In manual tune mode, the autosampler was 
shut off, pumping mode set to binary flow, the LC flow rate was set to 0.4 mL/min, the 
oven temperature set to 40 °C, and the mobile phase B concentration was set to 50%. In 
the MS method, “MRM” scan type was selected and all analyte ions and their respective 
DP, CE, and CXP values were entered. The source and gas parameters were set to the 
starting conditions: ion spray voltage set at 2500 V, temperature set at 350 °C, gas 1 and 2 
set at 30 °C, and curtain gas set at 20 °C. The duration of the scan was set to 20 minutes. 
After each scan, each of the parameters were optimized individually until the value that 
produced the best signal in the total ion chromatogram was obtained.  
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4.3.2 LC-MS/MS instrument Parameters 
Both compound and source optimized parameters obtained from the previously 
described method were used to build the LC-MS/MS acquisition method. The parameters 
that were established from the compound optimization and source optimization above were 
established and shown in Tables below; illustrating the final parent (Q1) masses, two 
product (Q2) masses, DP, CE, and CXP for each product ions. Table 2 shows the final 
MRM table used for all analytes, which were conducted in positive ionization mode. The 
MRM scan duration was set to 8 minutes. Table 3 shows optimized source and gas 
parameters. 
 29 
Table 2. Compound Optimization MRM Table. 
 
Analyte Retention Time 
Q1 
Mass 
(Da) 
Q3 (1) 
Mass 
(Da) 
Q3 (2) 
Mass 
(Da) 
DP 
(V) 
Q3 (1) 
CE (V) 
Q3 (1) 
CXP 
(V) 
Q3 (2) 
CE (V) 
Q3 (2) 
CXP 
(V) 
4-cyano CUMYL-
BUTINACA 4.40 361.2 226.2 119.2 62 29.71 39.59 33.31 19.95 
5F-3,5-AB-
PFUPPYCA 4.10 393 189.2 134.2 100 52.63 32.75 89.11 22.8 
5F-ADB-PINACA 3.98 363.3 346.3 233.2 56 14.14 9.91 35.06 38.99 
5F-PY-PINACA 4.10 304.3 233.3 145.1 78 27.50 39.7 50.80 24.16 
ADB-PINACA 4.39 345.2 328.3 215.3 52 13.33 19.05 35.06 36.79 
APP-PICA 4.25 378.2 361.3 214.3 56 14.12 10.83 26.66 36.84 
CUMYL-
THPINACA 4.47 378.2 260.2 243.3 65 16.02 14.52 28.77 43.91 
EMB-FUBINACA 4.88 398.2 324.3 109.2 72 21.90 18.20 57.14 18.16 
JWH-250 5.08 336.3 121.2 91.2 87 28.83 20.52 65.18 15.21 
MDMB-FUBICA 4.66 397.2 252.3 109.2 61 21.03 43.99 52.42 18.53 
MEP-CHMICA 4.93 371.3 240.4 55.3 60 20.8 39.96 82.38 7.68 
MO-CHMINACA 5.55 387.3 241.3 145.2 70 22.71 41.62 49.53 24.59 
NM2201 5.24 376.2 232.3 144.3 55 15.34 41.02 52.16 23.53 
PB-22 5.03 359.2 214.3 144.2 53 18.043 36.93 50.99 24.63 
RCS-8 5.54 376.2 121.3 91.2 104 32.85 20.22 74.63 15.05 
UR144 5.62 312.3 125.1 55.3 97 31.85 21.96 60.216 8.41 
XLR11 5.18 330.3 232.3 125.3 95 33.95 39.08 33.03 22.65 
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Table 3.  Optimized Ion Source/ Gas Parameters.  
 
Curtain 
Gas (oC) 
Collision Gas 
(oC) 
Ion Spray 
Voltage (V) 
Temperature 
(oC) 
Ion Source 
Gas 1 (oC) 
Ion Source 
Gas 2 (oC) 
25 High 2500 550 45 45 
 
This LC method used 0.1% formic acid in Millipore water (mobile phase A) and 
0.1% formic acid in LC grade acetonitrile (mobile phase B). In the LC parameter setting, 
max pressure was set to 5,000 psi, flow rate was set to 0.6 mL/min, and the starting 
percentage was set at 5% mobile phase B. Autosampler parameters are shown in Table 4.  
 
Table 4. Auto Sampler Parameters 
 
Rinsing 
Vol. 
Needle 
stroke 
Rinsing 
Speed 
Sampling 
Speed 
Purge 
Time 
Rinse 
Dip Time 
Cooler 
Temp. 
1000 uL 52 mm 35 uL/sec 3 uL/sec 25 min 5 sec 15 oC 
 
The method begins with a 10 min pre-equilibration to ensure the instrument and 
column conditions are met with each run. After a 10 uL sample injection, the %B 
concentration begins at 5% and ramps up to 95% B over time of 5.5 minutes as shown in 
Table 5. After 8 minutes, the %B concentration returns down to 5% starting condition and 
is held there for re-equilibration for approximately 1.0 min.  
 
Table 5. LC Time Program 
 
Time (min) Module Event Parameter (%) 
0.01 Pump B Conc. Pump B Conc. 5 
0.50 Pump B Conc. Pump B Conc. 5 
5.50 Pump B Conc. Pump B Conc. 95 
7.50 Pump B Conc. Pump B Conc. 95 
8.00 Pumps Pump B Conc. 5 
9.00 Controller Stop  
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4.3.3 Sample Preparation 
All CRM standards and internal standards were purchased from Cayman Chemical 
Company in either as neat solids (1 mg) or received in solution form (in either methanol or 
acetonitrile) reference standards in either 1mg/mL or 100 µg/mL. All neat samples were 
prepared with 1 mL of methanol to give a final concentration of 1 mg/mL. Stock solutions 
were prepared for each reference standard at a final concentration of 10,000 ng/mL and 
serially diluted to 1,000 ng/mL and 100 ng/mL. These stock solutions were used to 
prepared working solutions for calibration standards (0.1, 0.5, 1, 2, 5, 10, 15, and 25 ng/mL) 
and quality control (QC) standards (1, 3, 7, and 20 ng/mL) for the validation studies and 
shown in Table 6. The internal standards concentration was 7.5 ng/mL. .  
 
Table 6. Preparation of Calibration Curve and QC Samples. The table shows the final 
concentration of the calibrators and QC’s prepared prior to SLE sample preparation. All 
calibrator and QC samples contained each analyte. The internal standard solutions had a 
final concentration of 7.5 ng/mL containing three deuterated internal standards.  
 
Calibrators/ QC’s name Concentration (ng/mL) Internal Standard  
(ng/mL) 
Cal 1 0.1 7.5 
Cal 2 0.5 7.5 
Cal 3 1 7.5 
Cal 4 2 7.5 
Cal 5 5 7.5 
Cal 6 10 7.5 
Cal 7 15 7.5 
Cal 8 25 7.5 
Lower Limit QC 1 7.5 
Low QC 3 7.5 
Medium QC 7 7.5 
High QC 20 7.5 
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4.3.3.1 Sample Preparation – Supported Liquid Extraction (SLE) 
ISOLUTE SLE (1 mL capacity cartridges) from Biotage (Charlotte, NC)was 
performed on all samples for the removal of unwanted matrix components from human 
whole blood and to concentrate analytes of interest. Prior to SLE, each sample (300 uL) 
was pretreated with 300 uL of 50 mM ammonium acetate (pH 4) and was vortexed for 
approximately 30 seconds. The entire pre-treated sample (total vol. less than 1mL) was 
added to the SLE cartridge. Slight pressure was applied to each sample-containing SLE 
cartridge to help initiate absorption onto the sorbent bed. Samples were allowed to sit for 
5 minutes on the cartridge. Afterwards, each sample was eluted with 2.5 mL of ethyl 
acetate, allowed to sit for 5 minutes, and repeated elution with an additional 2.5 mL of 
ethyl acetate. The entire eluted sample was dried under compressed nitrogen at 40oC and 
reconstituted in 100 uL of 50:50 mobile phase. These samples were transferred into 
autosampler vials and placed in the autosample chamber (15oC).  
 
4.3.4 Method Validation 
All validation parameters were performed in similar to SWGTOX guidelines to 
determine the limit of detection (LOD), limit of quantitation (LOQ), linearity, accuracy, 
precision, carryover, dilution integrity, matrix interference, internal standard interference, 
and ionization suppression and ionization enhancement.74 Quantitative data analysis was 
performed using MultiQuantTM software (ver. 3.0.5373.0). UR144-d5, PB-22-d9, and 
XLR11-d5 deuterated internal standards were used to quantify 4-cyano CUMYL-
BUTINACA, 5-fluoro-3,5-ABPFUPPYCA, 5-fluoro ADB-PINACA, 5-fluoro PY-
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PINACA, ADB-PINACA, APP-PICA, CUMYL-THPINACA, EMB-FUNICACA, JWH-
250, MDMB-FUBICA, MEP-CHMICA, MO-CHMINACA, NM2201, PB-22, RCS-8, and 
UR144. 
 
4.3.4.1 Calibration Curve, LLOQ, LOD, Dilution Integrity and Carryover 
The calibration model was developed using a working range of concentrations for 
the calibration curve (8 non-zero calibrators) and evaluating the statistical parameters so 
that concentrations of unknown synthetic cannabinoids in human whole blood could be 
accurately and reproducibly calculated. Once the calibration model was developed, it was 
confirmed by performing five additional separate runs using this same calibration range.  
Once the calibration model was set, the lower limit of quantitation (LLOQ) was 
determined for each analyte in blood samples. The lowest non-zero calibrator for each 
analyte (n=9) was used to determine the LLOQ over nine separate linearity runs. Using the 
developed calibration model, the LLOQ concentrations for each of the samples were 
examined. Following SWGTOX recommendations,74 all quantitative values were defined 
within 20% accuracy in all three samples.  
LOD was determined for each analyte in three different blood lots. Four 
concentrations were used to determine the LOD (0.5, 0.1, 0.05, 0.025 ng/mL). These 
samples were prepared in duplicates and ran three times (n=24). The average (Xblank) and 
standard deviation (Sblank) of the signal from the blank matrix samples were used to 
determine the LOD. The calculations used to determine the LOD are given below. 
LOD = Xblank + 3.3(Sblank) 
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Dilution integrity of analytes was assessed for accuracy and reproducibility. Blood 
samples were spiked at 100 ng/mL and performed 1:50 and 1:10 for a final concentration 
of 2 ng/mL and 4 ng/mL, respectively. The dilutions were extracted in triplicate over five 
separate runs (n=15 at each dilution).  
Analyte carryover was assessed by analyzing blank matrix samples in triplicate 
after the highest calibrator (n=6). The highest calibrator was 25 ng/mL for all except MO-
CHMINACA at 15 ng/mL. All samples underwent SLE, reconstituted and run on the LC-
MS/MS method with subsequent blank samples in between each high concentration 
sample. The highest concentration that did not produce carryover in the blank samples were 
further confirmed by running the same sample three times with subsequent blank samples 
in between the high concentration sample.   
 
4.3.4.2 Bias and Precision 
Bias and precision studies were conducted to determine the accuracy and 
reproducibility of the method when calculating the concentrations of synthetic 
cannabinoids in human whole blood. Here we evaluated bias by preparing samples with 
concentrations of 1, 3, 7, and 20 ng/mL. Each sample was run five separate times. With the 
concentrations obtained, the grand mean and grand standard deviation in each run was 
calculated. The formula used to calculate bias is shown below: 
𝐵𝑖𝑎𝑠	(%) = *𝐺𝑟𝑎𝑛𝑑	𝑚𝑒𝑎𝑛	𝑜𝑓	𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑	𝑐𝑜𝑛𝑐.−𝑁𝑜𝑚𝑖𝑛𝑎𝑙	𝑐𝑜𝑛𝑐.𝑁𝑜𝑚𝑖𝑛𝑎𝑙	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 : 𝑥	100 
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The precision was determined in this method by assessing within-run precision and 
between-run precision by calculating the mean and the standard deviation of each 
concentration separately for each of the five runs. The calculations were used for each 
analyte present in the blood sample. Calculations for within-run and between-run precision 
is shown below:  
𝑊𝑖𝑡ℎ𝑖𝑛	𝑟𝑢𝑛	%𝐶𝑉 = 	 B𝑀𝑆𝑤𝑔𝐺𝑟𝑎𝑛𝑑	𝑚𝑒𝑎𝑛	𝑓𝑜𝑟	𝑒𝑎𝑐ℎ	𝑐𝑜𝑛𝑐. 	𝑥	100 
Between-run %CV =   	 BGHIJK(LKM)∗GHOJPQRLS	TURL	VWQ	URXY	XWLX. 		𝑥	100 
Where MSwg is mean square within groups, MSbg is the mean square between groups, and 
n is the number of observations in each group. 
 
4.3.4.3 Matrix Effects – Ionization Suppression/Enhancement & Recovery 
The effects of matrix on ionization suppression or enhancement of analyte signal 
intensity was investigated at low (0.5 ng/mL) and high concentrations (15 ng/mL). This 
experiment involves observing signal intensity in three different sets of samples: Neat 
samples, pre-extraction samples, and post-extraction addition of analytes in human whole 
blood. Neat samples were prepared at low and high concentrations, with internal standard, 
in mobile phase and injecting 6 times onto the LC-MS/MS.  
A pre-extraction samples was performed using pooled blood samples. The pre-
extracted samples involved spiking human blood at low and high concentrations, in 
triplicates, with 10 uL of internal standard, following normal SLE procedure, reconstituting 
in 50:50 (mobile phase A: mobile phase B), and injecting into the LC-MS/MS.  
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A post-extraction addition of analytes was also performed with 10 individual lots 
of whole blood samples. This approach can yield quantitative estimations of ionization 
suppression or enhancement that may potentially occur in a new quantitative method by 
comparing neat standards (Area set 1) with post-extracted samples (Area set 2). Here, each 
drug-free blood lot underwent normal SLE procedures, reconstituted in neat low (0.5 
ng/mL) and neat high (15 ng/mL), with internal standard and injected into the LC-MS/MS. 
Ion suppression or enhancement was observed if  ≥ ±25%. 
Ionization Suppression or Enhancement (%) = Z[QUR	WV	\U]	^[QUR	WV	\U]	M − 1_𝑥	100 
 Matrix recovery was evaluated using the same pre-extraction and post-extraction 
addition samples. By comparing pre-extraction addition samples to post-extraction 
addition samples, the percent recovery of each analyte can be assessed with our current 
method. The calculations used to determine percent recovery is shown below: 
Percent Recovery (%) = [QUR	`QUaUb]QRX]cWL	RSSc]cWL[QUR	`W\]aUb]QRX]cWL	RSSc]cWL 	𝑥	100 
4.3.4.4 Interference – Matrix Effects/ Internal standard/ Other Analytes 
Interference studies were performed to assess the effects of blood matrices, internal 
standards, and other commonly encountered analytes. To determine potential matrix 
interferences, analyte-free blood samples (without internal standards) was prepared using 
10 different blood lots. This was performed by aliquoting 300 uL of drug-free blood and 
performing supported-liquid extraction, eluting, evaporating, reconstitution in 100uL in 
50:50 (mobile phase A: mobile phase B) and injecting 10uL into the LC-MS/MS. The 
signal of analytes was monitored to observe the presence or absence of any false-positive 
identification, with an acceptable criterion below the LOQ.  
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To assess the effects of internal standard, two sets of blood were prepared: one 
blood matrix analyte-free with internal standard, and one blood matrix with analytes at high 
calibrator concentration (15 ng/mL) without internal standard. Each sample was prepared 
via supported-liquid extraction, reconstituted in 50:50 (mobile phase A: mobile phase B) 
and injected 10uL into the LC-MS/MS. The signal of analytes was observed in both sets to 
see if any stable isotopes posed as interferences in the LC-MS/MS method, with an 
acceptable criterion below the LOD.  
Other commonly encountered drugs were assessed to determine if they interfered 
with the LC-MS/MS method by causing false positives or suppressing the signal of 
expected analytes. The analytes involved in this study include: clonazepam, diazepam, 
(+)methadone, morphine, fentanyl, cocaine, amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA), 25I-NBOMe, and PCP. 25I-NBOMe was 
purchased from Lipomed. All other standards were purchased from Cerilliant. All 
standards had a stock concentration of 1 mg/mL and serially diluted to a working stock 
concentration of 30,000 ng/mL. 20uL of this working stock was added to drug-free human 
blood (at a final concentration of 2,000 ng/mL), with 10uL of internal standard and 
proceeded with supported-liquid extraction, reconstituted in 50:50 (mobile phase A: 
mobile phase B) and injected 10uL into the LC-MS/MS. The signal of analytes was 
observed to see if any analytes posed as a false positive interference in the LC-MS/MS 
method, with an acceptable criterion below the LOD.  
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Table 7. List of Interference Analytes. 10 drug compounds commonly encountered in 
forensic case work were chosen for the interference study. 
  
Interference 
Compounds Company Lot Number 
Stock 
Concentration 
(ng/mL) 
Clonazepam Cerilliant FE07131603 1mg/mL 
Diazepam Cerilliant FE05201602 1mg/mL 
(+) Methadone Cerilliant FE06221502 1mg/mL 
Morphine Cerilliant FE03191402 1mg/mL 
Fentanyl Cerilliant FE022508-01 1mg/mL 
Cocaine Cerilliant FE051012-01 1mg/mL 
Amphetamine Cerilliant FE07011403 1mg/mL 
MDMA Cerilliant FE043013-02 1mg/mL 
25I -NBOMe Lipomed 1557.1B1.1L1 1mg/mL 
PCP Cerilliant FE05291401 1mg/mL 
 
 
5. Results 
5.1 Detection of Analytes 
The total method length is 8 minutes and all analytes eluted between 3.8 and 5.8 
minutes. Overlap of chromatographic peaks was observed for similarly structured analytes 
(e.g. 5F-3,5-AB-PFUPPYCA and 5F-PY-PINACA), however, all analytes were positively 
identified via mass spectrometry fragmentation of precursor and product ions. Maximum 
ion ratio variance did not exceed 20%. 
  
 39 
Table 8. Retention Time for All Analytes.  
 
Analyte Retention time (min) 
5F-ADB-PINACA 3.98 
5F-3,5-AB-PFUPPYCA 4.10 
5F-PY-PINACA 4.10 
APP-PICA 4.25 
ADB-PINACA 4.39 
4-cyano CUMYL-BUTINACA 4.40 
CUMYL-THPINACA 4.47 
MDMB-FUBICA 4.66 
EMB-FUBINACA 4.88 
MEP-CHMICA 4.93 
PB-22-d9 5.00 
PB-22 5.03 
JWH-250 5.08 
XLR11-d5 5.16 
XLR11 5.18 
NM2201 5.24 
RCS-8 5.54 
MO-CHMINACA 5.55 
UR144-d5 5.59 
UR144 5.62 
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Figure 4. Total Extracted Ion Chromatogram in Blood. Results show the total 
extracted chromatogram (XIC) of all analytes including the internal standards in blood. 
All compounds elute between 3.8 minutes and 5.8 minutes. Analytes are eluted in the 
following order: 5-fluoro ADB-PINACA, 5-fluoro PY-PINACA, 5-fluoro-3,5-
ABPFUPPYCA, APP-PICA, ADB-PINACA, 4-cyano CUMYL-BUTINACA, CUMYL-
THPINACA, MDMB-FUBICA, EMB-FUBINACA, MEP-CHMICA, PB-22-d9, PB-22, 
JWH-250, XLR11-d5, XLR11, NM2201, RCS-8, MO-CHMINACA, UR144-d5, UR144. 
 
 
5.2  Method Validation 
5.2.1 Calibration Model  
Calibration curves containing all analytes were run over 5 separate runs in spiked 
drug-free human whole blood. A working range of 0.1 ng/mL to 25 ng/mL for analytes 
was established for APP-PICA and NM2201. Other analytes had an established working 
range of 0.5 ng/mL to 25 ng/mL which includes: 4-cyano CUMYL-BUTINACA, 5-fluoro-
3,5-ABPFUPPYCA, 5-fluoro ADB-PINACA, 5-fluoro PY-PINACA, ADB-PINACA, 
CUMYL-THPINACA, EMB-FUNICACA, JWH-250, MDMB-FUBICA, MEP-
CHMICA, PB-22, RCS-8, UR144, XLR11. MO-CHMINACA had an established working 
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range of 0.5 ng/mL to 15 ng/mL. Three internal standards used in this study include 
UR144-d5, XLR11-d5, PB-22-d9 using a weighting factor of 1/x. All analytes were set at 
linear models, except for PB-22, which were set as a quadratic model. The average R2 
values for each analyte was above of 0.998. A summary of these results is shown in Tables 
9 and 10.  
 
Table 9. Working Linear Dynamic Range and Regression Model for Each Analyte. 
 
Analytes Working Range 
(ng/mL) 
Regression 
Model 
4-cyano CUMYL-BUTINACA 0.5 - 25 Linear 
5F-3,5-AB-PFUPPYCA 0.5 - 25 Linear 
5F-ADB-PINACA 0.5 - 25 Linear 
5F-PY-PINACA 0.5 - 25 Linear 
ADB-PINACA 0.5 - 25 Linear 
APP-PICA 0.1 - 25 Linear 
CUMYL-THPINACA 0.5 - 25 Linear 
EMB-FUBINACA 0.5 - 25 Linear 
JWH-250 0.5 - 25 Linear 
MDMB-FUBICA 0.5 - 25 Linear 
MEP-CHMICA 0.5 - 25 Linear 
MO-CHMINACA 0.5 - 15 Linear 
NM2201 0.1 - 25 Linear 
PB-22 0.5 - 25 Quadratic 
RCS-8 0.5 - 25 Linear 
UR144 0.5 - 25 Linear 
XLR11 0.5 - 25 Linear 
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Table 10. Average R2 values of Five Calibration Curves of all Analytes in Blood. 
 
Analyte Run 1 Run 2 Run 3 Run 4 Run 5 Average 
4-cyano CUMYL-
BUTINACA 0.99859 0.99933 0.9979 0.99971 0.99995 0.9990 
5F-3,5-AB-
PFUPPYCA 0.99952 0.99757 0.99929 0.99779 0.9992 0.9987 
5F-ADB-PINACA 0.99952 0.99844 0.99970 0.99824 0.99832 0.9988 
5F-PY-PINACA 0.99967 0.99910 0.99955 0.99967 0.99970 0.9995 
ADB-PINACA 0.99859 0.99933 0.99979 0.99971 0.99995 0.9995 
APP-PICA 0.99968 0.99900 0.99981 0.99920 0.99969 0.9996 
CUMYL-THPINACA 0.99772 0.99964 0.99988 0.99949 0.99944 0.9992 
EMB-FUBINACA 0.99763 0.99659 0.99920 0.99908 0.99815 0.9981 
JWH-250 0.99942 0.99963 0.99959 0.99987 0.99959 0.9996 
MDMB-FUBICA 0.99792 0.99998 0.99946 0.99910 0.99482 0.9983 
MEP-CHMICA 0.99788 0.99747 0.99954 0.99952 0.99774 0.9984 
MO-CHMINACA 0.99970 0.99927 0.99980 0.99995 0.99977 0.9997 
NM2201 0.99969 0.99977 0.99896 0.99966 0.99895 0.9994 
PB-22 0.99961 0.99983 0.99995 0.99989 0.99994 0.9998 
RCS-8 0.99825 0.99931 0.99988 0.99955 0.99981 0.9994 
UR144 0.99918 0.99957 0.99985 0.99930 0.99961 0.9995 
XLR11 0.999859 0.99823 0.99976 0.99981 0.99925 0.9991 
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5.2.2 Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
Using the previously established calibration model with a working range of 0.1 
ng/mL to 25 ng/mL, the limit of quantitation (LOQ) was determined for each analyte. The 
LOQ was determined as the lowest concentration that could be quantified within a 20% 
accuracy in spiked drug-free human whole blood. A LOQ of 0.1 ng/mL was determined 
for analytes APP-PICA, EMB-FUBINACA, NM2201, and XLR11. A LOQ of 0.5 ng/mL 
was determined for analytes 4-cyano CUMYL-BUTINACA, 5F-3,5-AB-PFUPPYCA, 5F-
ADB-PINACA, 5F-PY-PINACA, ADB-PINACA, CUMYL-THPINACA, JWH-250, 
MDMB-FUBICA, MEP-CHMICA, MO-CHMINACA, PB-22, RCS-8, and UR144.  
LOD was determined for each analyte by running each analyte at decreasing 
concentrations: 0.5, 0.1, 0.05, 0.025 ng/mL to determine a signal greater than the average 
signal of the blank matrix sample plus 3.3 times the standard deviation. The LOD was 
determined to be 0.1 ng/mL for analyte 4-cyano CUMYL-BUTINACA, 0.05 ng/mL for 
analytes MDMB-FUBICA and MEPCHMICA, and 0.025 ng/mL for analytes 5F-3,5-AB-
PFUPPYCA, 5F-ADB-PINACA, 5F-PY-PINACA, ADB-PINACA, APP-PICA, 
CUMYL-THPINACA, EMB-FUBINACA, JWH-250, MDMB-FUBICA, JWH-250, MO-
CHMINACA, NM2201, PB-22, RCS-8, UR144, and XLR11. LOD and LOQ data are 
summarized in Table 11 below.  
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Table 11. Limit of Quantitation and Limit of Detection for Each Analyte.   
 
Analytes Limit of Quantitation 
(ng/mL) 
Limit of Detection 
(ng/mL) 
4-cyano CUMYL-BUTINACA 0.5 0.1 
5F-3,5-AB-PFUPPYCA 0.5 0.025 
5F-ADB-PINACA 0.5 0.025 
5F-PY-PINACA 0.5 0.025 
ADB-PINACA 0.5 0.025 
APP-PICA 0.1 0.025 
CUMYL-THPINACA 0.5 0.025 
EMB-FUBINACA 0.5 0.025 
JWH-250 0.5 0.025 
MDMB-FUBICA 0.5 0.05 
MEP-CHMICA 0.5 0.05 
MO-CHMINACA 0.5 0.025 
NM2201 0.1 0.025 
PB-22 0.5 0.025 
RCS-8 0.5 0.025 
UR144 0.5 0.025 
XLR11 0.1 0.025 
 
5.2.3 Analyte Carryover 
Determination of carryover was assessed by monitoring double blank samples 
(blood matrix samples that were fortified without analytes and internal standards) that were 
run immediately after the highest calibrator. Signal intensity of all analytes in the double 
blank was determined to be lower than the established limit of detection for each analyte. 
No carryover was observed in any of the double blank matrix samples.  
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5.2.4 Dilution Integrity 
Dilution integrity of fortified matrix was investigated in cases where samples have 
exceedingly high concentrations that are beyond the linear dynamic range. In this case, 
fortified matrix was spiked at 100 ng/mL and diluted by 1:50 and 1:10, with final 
concentrations at 2 ng/mL and 10 ng/mL, respectively. Dilution samples were prepared in 
triplicates and ran over the course of 5 separate runs.  According to SWGTOX guidelines, 
accuracy and %CV and bias must fall within ±20%. All analytes, with the exception of 
NM2201 1:50 accuracy (125.08%), met these conditions as shown in table 12.  
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Table 12. Dilution integrity of fortified matrix at 1:50 (2 ng/mL) and 1:10 (10 
ng/mL). Dilution integrity of each analyte was investigated over a course of 5 separate 
runs. 
 
 1:50 (2 ng/mL) 1:10 (10 ng/mL) 
 
Analyte 
Average 
(ng/mL) 
STDEV 
(ng/mL) Accuracy %CV 
Average 
(ng/mL) 
STDEV 
(ng/mL) 
%Accuracy %CV 
4-cyano 
CUMYL-
BUTINACA 
2.03 0.17 101.33 8.46 9.60 0.83 98.83 8.68 
5F-3,5-AB-
PFUPPYCA 1.90 0.17 95.17 9.04 9.54 1.28 95.40 13.43 
5F-ADB-
PINACA 1.91 0.19 95.04 10.11 9.52 1.14 94.42 11.98 
5F-PY-
PINACA 1.90 0.19 94.88 10.27 9.40 0.50 94.03 5.28 
ADB-
PINACA 1.86 0.15 92.89 8.24 9.35 0.73 93.52 7.76 
APP-PICA 1.76 0.15 88.06 8.67 9.15 0.90 91.50 9.84 
CUMYL-
THPINACA 1.90 0.13 95.18 6.90 9.40 0.72 93.95 7.67 
EMB-
FUBINACA 2.37 0.21 118.57 8.78 11.11 0.92 111.11 8.28 
JWH-250 2.06 0.10 102.83 4.79 10.18 0.27 101.77 2.62 
MDMB-
FUBICA 2.16 0.13 108.01 6.01 11.12 0.51 111.18 4.58 
MEP-
CHMICA 2.25 0.15 112.50 6.58 10.83 0.64 108.33 5.93 
MO-
CHMINACA 2.00 0.24 99.92 12.14 9.69 0.87 96.92 8.95 
NM2201 2.50 0.18 125.08 7.25 12.50 1.55 115.25 12.40 
PB-22 2.20 0.10 110.00 4.60 10.70 0.41 106.95 3.84 
RCS-8 2.25 0.11 112.30 4.78 10.43 0.59 104.28 5.62 
UR144 2.28 0.07 113.87 3.29 10.75 0.41 107.54 3.81 
XLR11 2.19 0.05 109.61 2.39 11.00 0.67 109.98 6.05 
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5.2.5 Bias and Precision 
Concentrations at 1.0 ng/mL, 3.0 ng/mL, 7.0 ng/mL, and 20 ng/mL were evaluated 
for bias and precision in fortified blood matrix. Each sample concentration was prepared 
in triplicates and analyzed over the course of five separate runs. Bias is the measure of the 
closeness in value to the true expected value, and precision is the measure of 
reproducibility. Within-run precision is calculated for each concentration separately for 
each of the five runs and is the precision between the three replicates within a single run at 
each concentration. Between-run precision is calculated for each concentration over five 
runs and is the precision between all the replicates at each concentration.  
 
Table 13. Bias and Between-Run Precision for all Analytes in Fortified Matrix 
Blood. 
 
1.0 ng/mL Average (ng/mL) 
STDEV 
(ng/mL) Bias (%) CV (%) 
4-cyano CUMYL-
BUTINACA 1.05 0.08 4.92 7.29 
5F-3,5-AB-
PFUPPYCA 1.05 0.10 4.86 9.55 
5F-ADB-PINACA 1.10 0.06 10.19 5.53 
5F-PY-PINACA 1.06 0.10 6.14 9.07 
ADB-PINACA 1.08 0.08 8.16 7.21 
APP-PICA 1.07 0.08 7.04 7.14 
CUMYL-
THPINACA 1.04 0.08 3.72 8.03 
EMB-FUBINACA 1.09 0.08 8.79 7.31 
JWH-250 1.04 0.08 3.78 7.57 
MDMB-FUBICA 1.07 0.08 6.72 7.87 
MEP-CHMICA 1.08 0.05 7.75 4.89 
MO-CHMINACA 0.98 0.10 -1.72 10.48 
NM2201 1.08 0.06 7.59 5.90 
PB-22 1.05 0.05 5.19 4.63 
RCS-8 1.02 0.09 1.98 8.47 
UR144 1.06 0.06 5.83 6.04 
XLR11 1.04 0.07 4.01 6.65 
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Table 13. Bias and Between-Run Precision for all Analytes in Fortified Matrix 
Blood. (cont.) 
 
3.0 ng/mL Average (ng/mL) 
STDEV 
(ng/mL) Bias (%) CV (%) 
4-cyano CUMYL-
BUTINACA 3.16 0.14 5.35 7.29 
5F-3,5-AB-
PFUPPYCA 3.11 0.26 3.68 8.22 
5F-ADB-PINACA 3.23 0.19 7.71 5.92 
5F-PY-PINACA 3.25 0.16 6.14 4.97 
ADB-PINACA 3.20 0.14 6.58 4.46 
APP-PICA 3.14 0.22 4.60 6.86 
CUMYL-
THPINACA 3.19 0.15 6.19 4.81 
EMB-FUBINACA 3.35 0.20 11.52 5.89 
JWH-250 3.21 0.13 7.01 4.11 
MDMB-FUBICA 3.27 0.16 8.96 4.99 
MEP-CHMICA 3.33 0.17 7.75 5.03 
MO-CHMINACA 3.05 0.31 1.63 10.08 
NM2201 3.09 0.27 2.87 8.77 
PB-22 3.04 0.17 1.22 5.62 
RCS-8 3.11 0.13 3.54 4.14 
UR144 3.34 0.17 11.45 5.12 
XLR11 3.12 0.25 3.86 7.92 
7.0 ng/mL Average (ng/mL) 
STDEV 
(ng/mL) Bias (%) CV (%) 
4-cyano CUMYL-
BUTINACA 7.34 0.32 4.88 4.38 
5F-3,5-AB-
PFUPPYCA 7.29 0.47 4.12 6.39 
5F-ADB-PINACA 7.55 0.65 7.92 8.56 
5F-PY-PINACA 8.03 1.20 14.73 14.89 
ADB-PINACA 7.42 0.31 5.95 4.13 
APP-PICA 7.25 0.37 3.55 5.08 
CUMYL-
THPINACA 7.49 0.21 7.00 2.78 
EMB-FUBINACA 7.35 0.36 8.79 4.83 
JWH-250 7.47 0.33 6.65 4.47 
MDMB-FUBICA 7.35 0.46 5.07 6.31 
MEP-CHMICA 7.64 0.28 9.08 3.62 
MO-CHMINACA 7.18 0.46 2.61 6.45 
NM2201 7.24 0.37 3.42 5.13 
PB-22 7.11 0.26 1.58 3.68 
RCS-8 7.16 0.16 2.29 2.19 
UR144 7.81 0.31 11.60 4.01 
XLR11 7.25 0.48 3.63 6.67 
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Table 13. Bias and Between-Run Precision for all Analytes in Fortified Matrix 
Blood. (cont.) 
 
20 ng/mL Average (ng/mL) 
STDEV 
(ng/mL) Bias (%) CV (%) 
4-cyano CUMYL-
BUTINACA 19.84 1.12 -0.81 5.62 
5F-3,5-AB-
PFUPPYCA 20.12 1.95 0.60 9.67 
5F-ADB-PINACA 21.11 1.52 5.54 7.18 
5F-PY-PINACA 21.38 1.23 6.92 5.75 
ADB-PINACA 20.27 0.71 1.34 3.48 
APP-PICA 20.39 0.35 1.93 1.70 
CUMYL-
THPINACA 20.19 0.74 0.95 3.65 
EMB-FUBINACA 19.37 1.39 -3.17 7.18 
JWH-250 19.97 0.94 -0.16 4.69 
MDMB-FUBICA 19.52 1.52 -2.37 7.77 
MEP-CHMICA 19.93 1.24 -0.36 6.24 
MO-CHMINACA N/A N/A N/A N/A 
NM2201 19.21 1.56 -3.93 8.09 
PB-22 20.42 1.15 2.11 5.63 
RCS-8 19.24 1.16 -3.80 6.05 
UR144 20.17 0.37 0.85 1.81 
XLR11 19.31 1.19 -3.44 6.17 
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Table 14. Within-Run Precision Results for All Analytes in Matrix Blood. 
 
1.0 ng/mL %CV Run 1 %CV Run 2 %CV Run 3 %CV Run 4 %CV Run 5 
4-cyano 
CUMYL-
BUTINACA 
4.97 6.05 8.88 4.64 0.83 
5F-3,5-AB-
PFUPPYCA 3.52 1.64 3.36 3.85 2.50 
5F-ADB-
PINACA 3.52 2.46 8.11 2.17 8.42 
5F-PY-
PINACA 3.54 3.19 5.11 3.90 4.30 
ADB-PINACA 
 5.84 4.69 8.03 4.72 4.43 
APP-PICA 
 1.09 3.19 8.30 11.34 7.10 
CUMYL-
THPINACA 4.72 2.76 7.09 9.31 1.38 
EMB-
FUBINACA 0.41 5.07 5.28 0.67 3.51 
JWH-250 
 4.33 7.55 1.54 2.81 3.31 
MDMB-
FUBICA 2.88 6.46 4.93 1.35 10.42 
MEP-CHMICA 
 4.54 3.94 4.47 6.51 5.60 
MO-
CHMINACA 6.74 6.25 7.26 7.32 6.84 
NM2201 0.98 5.29 3.67 6.32 9.30 
PB-22 1.76 4.77 3.59 4.43 5.65 
RCS-8 6.23 7.22 6.16 1.56 3.11 
UR144 2.33 3.84 1.40 5.71 4.74 
XLR11 0.59 4.91 4.80 1.05 4.02 
3.0 ng/mL %CV Run 1 %CV Run 2 %CV Run 3 %CV Run 4 %CV Run 5 
4-cyano 
CUMYL-
BUTINACA 
4.04 0.49 5.22 1.93 2.93 
5F-3,5-AB-
PFUPPYCA 0.44 2.90 3.46 3.80 5.49 
5F-ADB-
PINACA 
0.44 0.82 6.62 4.76 3.47 
5F-PY-
PINACA 
1.15 1.39 3.86 2.38 1.67 
ADB-PINACA 6.94 2.95 2.15 0.30 0.06 
APP-PICA 5.99 0.54 2.54 2.07 6.97 
CUMYL-
THPINACA 
3.98 2.42 3.68 4.96 3.01 
EMB-
FUBINACA 
5.54 2.57 3.39 0.74 6.32 
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Table 14. Within-Run Precision Results for All Analytes in Matrix Blood. (cont.) 
 
JWH-250 1.29 0.40 2.27 0.57 3.27 
MDMB-FUBICA 3.24 3.68 1.60 3.42 6.07 
MEP-CHMICA 3.62 4.88 4.35 2.90 3.16 
MO-CHMINACA 2.38 2.59 3.94 2.16 0.43 
NM2201 1.41 7.98 5.44 1.64 7.09 
PB-22 3.15 1.74 2.18 4.07 3.83 
RCS-8 4.79 3.95 2.47 2.77 3.11 
UR144 4.00 1.92 3.29 3.30 3.39 
XLR11 3.96 4.31 2.86 3.54 3.62 
7.0 ng/mL %CV Run 1 %CV Run 2 %CV Run 3 %CV Run 4 %CV Run 5 
4-cyano CUMYL-
BUTINACA 6.30 2.07 0.40 3.00 0.64 
5F-3,5-AB-PFUPPYCA 6.10 2.63 2.08 4.80 1.78 
5F-ADB-PINACA 1.44 3.41 6.43 0.97 5.82 
5F-PY-PINACA 1.00 5.02 2.89 4.18 6.22 
ADB-PINACA 2.12 4.37 3.09 1.35 4.64 
APP-PICA 5.41 3.07 1.04 6.14 5.05 
CUMYL-THPINACA 3.82 1.44 4.25 2.03 1.86 
EMB-FUBINACA 3.55 1.37 1.81 1.47 0.72 
JWH-250 1.17 4.30 3.83 1.91 3.63 
MDMB-FUBICA 3.39 2.43 0.008 3.49 3.00 
MEP-CHMICA 0.73 1.90 3.43 1.89 2.32 
MO-CHMINACA 2.83 5.79 2.21 1.56 4.39 
NM2201 1.24 2.28 7.64 1.12 8.94 
PB-22 3.20 1.66 2.46 1.58 0.89 
RCS-8 1.67 1.17 2.57 1.48 4.13 
UR144 6.32 2.49 0.33 1.16 4.79 
XLR11 5.23 3.40 1.54 1.29 4.76 
20.0 ng/mL %CV Run 1 %CV Run 2 %CV Run 3 %CV Run 4 %CV Run 5 
4-cyano CUMYL-
BUTINACA 1.46 3.28 1.99 5.73 5.75 
5F-3,5-AB-PFUPPYCA 3.12 1.68 3.11 8.58 1.90 
5F-ADB-PINACA 3.12 1.97 3.15 5.25 4.69 
5F-PY-PINACA 0.47 3.19 1.07 3.67 1.96 
ADB-PINACA 3.44 2.08 0.80 1.10 4.25 
APP-PICA 2.04 0.35 2.39 2.00 1.46 
CUMYL-THPINACA 2.93 4.09 0.93 4.10 5.56 
EMB-FUBINACA 3.25 0.81 3.42 5.89 6.12 
JWH-250 3.26 1.74 3.93 4.19 6.58 
MDMB-FUBICA 1.80 3.96 1.28 9.51 4.08 
MEP-CHMICA 3.10 0.96 2.92 11.05 2.78 
MO-CHMINACA N/A N/A N/A N/A N/A 
NM2201 1.21 3.79 5.13 14.36 10.44 
PB-22 6.08 3.78 0.20 2.24 4.21 
RCS-8 2.57 2.22 1.26 0.92 5.01 
UR144 0.87 1.51 0.31 0.81 0.72 
XLR11 4.18 1.54 0.49 8.04 4.27 
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5.2.6 Matrix Effect – Ionization Suppression/Enhancement & Recovery 
 
Matrix suppression was observed at low and high concentrations with analytes 4-
cyano CUMYL-BUTINACA, 5F-PY-PINACA, CYMYL-THPINACA, NM2201, and 
RCS-8. Suppression of ionization was observed at high concentration for JWH-250 and 
MEP-CHMICA (Table 15). 
Percent extraction recovery is shown in Table 16. Percent recovery ranged from 
57% UR144 to 85% for ADB-PINCA at the low concentration. Percent recovery ranged 
from 55% EMB-FUBINACA to 83% 5F-ADB-PINACA at the high concentration.  
Table 15. Matrix Effect – Ionization Suppression/ Enhancement Results. 
 
 Low Concentration  (0.5 ng/mL) 
High Concentration 
(15 ng/mL) 
Analyte Supp/Enh. (%) Supp/Enh. (%) 
4-cyano CUMYL-BUTINACA -46.47 -43.71 
5F-3,5-AB-PFUPPYCA 2.22 -0.06 
5F-ADB-PINACA -0.63 -5.87 
5F-PY-PINACA -11.38 -28.60 
ADB-PINACA -6.20 -11.68 
APP-PICA -2.94 -15.18 
CUMYL-THPINACA -41.95 -39.71 
EMB-FUBINACA -47.39 -41.20 
JWH-250 -53.47 -34.12 
MDMB-FUBICA -25.66 -12.00 
MEP-CHMICA -40.87 -23.07 
MO-CHMINACA -33.70 -4.24 
NM2201 -57.78 -58.02 
PB-22 -46.80 -17.32 
RCS-8 -43.99 -32.52 
UR144 -13.99 -10.69 
XLR11 -59.03 -54.26 
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Table 16. Percent Extraction Recovery Results for All Analytes. 
 
 Low Concentration (0.5 ng/mL) High Concentration (15 ng/mL) 
 
Analyte 
 
Pre-
Extraction 
Average Area  
Post-
Extraction 
Average 
Area 
Extraction 
Recovery 
(%) 
Pre-
Extraction
Average 
Area  
Post-
Extraction 
Average 
Area 
Extraction 
Recovery 
(%) 
4-cyano CUMYL-
BUTINACA 4.38E+05 6.19E+05 70.81 2.79E+06 3.75E+06 74.58 
5F-3,5-AB-
PFUPPYCA 3.43E+04 3.43E+04 76.83 2.33E+05 2.98E+05 78.44 
5F-ADB-PINACA 1.19E+05 1.49E+05 80.20 8.51E+05 1.02E+06 83.36 
5F-PY-PINACA 1.45E+06 1.87E+06 77.62 6.54E+06 9.68E+06 67.59 
ADB-PINACA 5.92E+05 6.96E+05 85.09 3.27E+06 4.08E+06 80.13 
APP-PICA 1.15E+05 1.44E+05 79.49 6.43E+05 9.39E+05 68.41 
CUMYL-
THPINACA 6.04E+05 8.26E+05 73.10 3.62E+06 3.62E+06 77.85 
EMB-FUBINACA 3.03E+05 4.04E+05 75.19 1.52E+06 2.77E+06 54.92 
JWH-250 7.89E+05 1.36E+06 58.01 4.05E+06 6.47E+06 62.52 
MDMB-FUBICA 5.31E+05 7.75E+05 68.59 2.91E+06 4.09E+06 69.87 
MEP-CHMICA 5.74E+05 8.22E+05 69.87 2.87E+06 4.25E+06 67.38 
MO-CHMINACA 6.94E+05 9.51E+05 73.00 3.32E+06 5.57E+06 59.57 
NM2201 1.04E+05 1.50E+05 69.00 6.38E+05 1.01E+06 63.37 
PB-22 9.12E+05 1.32E+06 68.89 4.30E+06 4.30E+06 59.21 
RCS-8 5.01E+05 5.01E+05 60.82 2.89E+06 4.63E+06 62.43 
UR144 9.59E+05 1.67E+06 57.45 5.45E+06 7.18E+06 60.56 
XLR11 1.21E+05 1.80E+05 67.08 7.09E+05 1.01E+06 70.54 
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5.2.7 Interference from Matrix, Internal Standard, and Other Analytes 
5.2.7.1 Matrix Interference 
Ten different lots of blood was used and analyzed without the presence of 
analytes and internal standards to determine any presence of matrix interferences that 
would produce a false positive identification of analytes. The acceptance criteria for 
matrix interference for each blood lot was determined by having signal intensity less than 
that of the limit of detection. Results show that each of the 10 blood lots did not produce 
any interference (table 17). 
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Table 17. Interference – Matrix Effect Results. Signal intensities of 10 blood matrices 
have accepted ranges below each analyte’s LOD level.   
 
Analyte Lot 1 Lot 2 Lot 3 Lot 4 Lot 5 Lot 6 Lot 7 Lot 8 Lot 9 Lot 10 
4-cyano 
CUMYL-
BUTINACA 
4.42E+03 4.60E+03 3.16E+03 4.75E+03 2.05E+03 1.42E+03 3.21E+03 3.82E+03 3.38E+03 1.04E+04 
5F-3,5-AB-
PFUPPYCA 6.96E+02 6.40E+02 7.89E+02 9.44E+02 1.31E+04 2.12E+03 6.59E+02 4.41E+02 1.52E+03 7.51E+02 
5F-ADB-
PINACA 6.39E+03 3.62E+03 3.69E+03 5.50E+03 3.80E+03 5.81E+03 1.63E+03 7.29E+03 5.30E+03 4.31E+03 
5F-PY-
PINACA 3.51E+02 2.63E+02 1.80E+03 4.28E+03 4.61E+03 8.69E+02 2.67E+03 6.11E+02 5.84E+03 1.51E+04 
ADB-
PINACA 1.03E+04 1.85E+04 8.44E+03 1.62E+04 1.22E+04 8.71E+03 7.82E+03 4.95E+03 7.26E+03 1.15E+04 
APP-PICA 1.81E+03 2.09E+03 1.02E+04 8.65E+03 3.15E+03 2.31E+03 2.68E+03 1.37E+04 3.39E+03 7.93E+03 
CUMYL-
THPINACA 2.03E+02 2.60E+02 7.72E+02 8.29E+02 2.91E+03 7.82E+02 1.84E+03 8.72E+02 5.14E+03 1.18E+04 
EMB-
FUBINACA 2.66E+03 5.98E+03 5.16E+03 1.98E+03 8.34E+03 3.01E+03 2.81E+03 2.05E+03 1.90E+03 4.50E+03 
JWH-250 7.77E+03 1.19E+03 3.79E+03 1.53E+04 3.14E+03 1.91E+04 2.09E+03 8.05E+03 3.64E+03 9.25E+03 
MDMB-
FUBICA 1.58E+02 1.51E+02 4.22E+02 5.94E+02 1.24E+03 3.15E+02 3.77E+02 1.08E+03 2.25E+03 7.66E+03 
MEP-
CHMICA 5.78E+02 4.40E+02 2.44E+02 4.90E+02 7.70E+02 7.00E+02 3.85E+02 6.63E+02 1.96E+03 6.58E+03 
MO-
CHMINACA 2.05E+03 4.89E+03 2.00E+03 1.52E+03 3.79E+03 3.19E+03 9.25E+02 6.18E+03 3.85E+03 1.20E+04 
NM2201 1.77E+02 3.11E+02 3.68E+02 1.56E+02 2.56E+02 2.76E+02 1.38E+02 2.55E+02 1.75E+02 1.31E+03 
PB-22 1.90E+03 1.91E+03 5.21E+02 1.18E+03 2.44E+03 3.28E+03 4.06E+02 2.26E+03 5.24E+03 9.39E+03 
RCS-8 8.45E+03 8.00E+03 3.97E+03 2.13E+04 2.51E+04 8.41E+05 1.36E+03 3.71E+03 2.95E+03 8.77E+03 
UR144 1.65E+03 6.13E+03 2.40E+03 4.97E+02 5.91E+03 1.44E+04 2.29E+03 9.67E+03 1.91E+04 1.19E+04 
XLR11 9.61E+02 1.36E+03 1.42E+03 1.20E+03 1.30E+03 4.79E+03 1.69E+03 4.59E+03 6.47E+03 6.28E+03 
 
5.2.7.2 Internal Standard Interference 
To determine if the presence of any stable isotope would interfere with the current 
method, internal standards were used without the presence of any analytes. The signal 
intensity for each analyte was observed, with acceptable levels below the LOD.  No 
interferences were present from analysis of deuterated internal standards.   
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Figure 6. Total Extraction Ion Chromatograph of Blank Blood with Only Internal-
standards.  
  
 
 
5.2.7.3 Other Analyte Interference 
Interferences of other commonly encountered compounds were used to assess the 
potential of any false positive signals. Here, 10 different drug compounds were used in 
this study at 2,000 ng/mL, which include: clonazepam, diazepam, (+) methadone, 
morphine, fentanyl, cocaine, amphetamine, 3,4-methylenedioxymethamphetamine 
(MDMA), 25I-NBOMe, and PCP. Signal intensity was observed to determine if 
compounds produced a signal intensity greater than the established LOD for each analyte. 
Chromatographic data show interference signal with ADB-PINACA. 
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Figure 7. Interference of Other Analytes. Total Extracted Ion Chromatograph of Post-
spiked blood with 10 commonly encountered drugs at high concentrations (2,000 ng/mL). 
Results show no indication of false identification.   
 
 
6. Discussion 
6.1 Detection of Analytes 
Due to the large number of synthetic cannabinoids, all analytes chosen for this study 
were based off the popularity and reoccurrence of certain synthetic cannabinoid 
compounds. Unfortunately, because many compounds are relatively new, many of these 
compounds do not have an associated certified reference deuterated internal standard.  
 In this method, two fragmented transition ions were used for the detection of each 
analyte. Two transition ions were used in this method to determine the best signal-to-noise 
ratio; the first most abundant signal-to-noise ratio used for quantitative analysis and the 
second most abundant signal-to-noise ratio was used for qualitative analysis. With this 
method, all analytes eluted between 3.8 and 5.8 minutes, with a total method length of 8 
minutes.  
 In the beginning of this study, method development was assessed looking at 19 
synthetic cannabinoids. However, two compounds (5F-MDMB-PICA and 5F-PB-22) 
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shared similar retention time and had similar parent (Q1) and transition (Q3) ions. Because 
of these qualities, the two compounds could not be distinguished from one another.  
 
6.2 Method Validation Parameters 
The calibration model was assessed using a range of concentrations that produced 
the best linear or quadratic regression which was also accurate and reproducible. A 
weighting of 1/x was used with all calibration models in both linear and quadratic curves 
due to variation at lower concentrations. Only PB-22 produced the best calibration curve 
using quadratic regression models. The rest had linear regression models. 
 The limit of quantitation was determined as the lowest quantifiable point on the 
calibration model. Synthetic cannabinoids have been determined to have a very short half-
life in the human body.72  Therefore, there is a need for analytical methods to detect the 
presence of synthetic cannabinoids at sub-nano levels. Most analytes had a determined 
limit of quantitation of 0.5 ng/mL; other analytes were quantifiable at 0.1 ng/mL as shown 
in table 9. Most analytes had an upper-limit of 25 ng/mL and others had 15 ng/mL. 
According to SWGTOX guidelines, a calibration model is required to have 6 non-zero 
calibration points. Although some analytes failed to quantify at 0.1 ng/mL (cal 1) and 
others at 25 ng/mL (cal 8), dropping these calibration points did not affect the acceptance 
criteria. 
 The limit of detection was determined for each analyte by preparing pre-extraction 
addition samples at decreasing intervals of 0.5, 0.1, 0.05, and 0.025 ng/mL. The signal-to-
noise that produce an intensity of 3.3 times the noise of the blank was determined to be the 
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LOD. Most analytes were determined to have an LOD of 0.025 ng/mL; very few had higher 
LOD’s. MDMB-FUBICA and MEP-CHMICA both had a limit of detection of 0.05 ng/mL 
and 4-cyano CUMYL-BUTINACA had an LOD of 0.1 ng/mL as shown in table 11.  
 Carry-over was assessed in this method by observing blank matrix samples 
immediately following the highest calibration point. Carry-over was not observed in this 
method. However, further evaluation of analyte carry-over should be assessed at higher 
concentrations to determine the maximum concentration where carry-over may be an issue.  
 Bias and precision was assessed for all analytes. The acceptance criterion was such 
that the %Bias and %CV for all analyte did not exceed ±20%. As shown in table 13, the 
bias and precision for all analytes fell within accepted ranges. , MO-CHMINACA had an 
upper-limit of 15 ng/mL and therefore does not have precision and accuracy calculations 
at  20 ng/mL QC. .  
 Extraction recovery was assessed with this method to determine the efficiency of 
the SLE procedure. Because sample preparation techniques may exhibit some sample loss, 
percent recovery was assessed to determine the amount of sample recovery. This was done 
by evaluating all analytes at low (0.5 ng/mL) and high (15 ng/mL) concentrations for both 
pre-extraction- and post-extraction addition samples. Although other sample preparation 
techniques may offer greater sample recovery (e.g. liquid-liquid extraction), it is a time-
costly method. Other conventional sample preparation methods include solid-phase 
extraction. However, with this developed SLE extraction method, the total sample 
preparation time was cut down by more than half. This was possible by eliminating the 
need for conditioning and washing steps in the SLE sample preparation method. 
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 Ionization suppression and enhancement was evaluated in this study to determine 
any interference from matrix effects. Table 15 shows some of variation (analyte specific) 
in ionization suppression. Two analytes (ADB-PINACA and APP-PICA) show minor 
ionization enhancement; the rest of the analytes exhibited minor ionization suppression. 
One analyte, NM2201, had notably significant ionization suppression. However, the degree 
of ionization suppression and enhancement did not affect the other validation parameters.  
 
6.2.1 Interferences 
Interference studies involving matrix effect, internal standard, and other analytes 
were also assessed to determine the reliability of the method. Ten different sources of blood 
matrix were run on the method without the presence of any analytes or internal standards 
to assess the matrix effect. As shown in table 17, the results show no potential source of 
matrix interferences, with signal intensities less than the established LOD for each analyte. 
However, chromatography and mass spectral data show slight presence of JWH-250 or the 
presence of RCS-8, which were lot specific, as shown in Appendix C. However, because 
the signal intensities calculated fall below the expected limit of detection, we can conclude 
there is no matrix interferences present.   
Interferences of internal standard was also assessed by running samples fortified 
with only internal standards without the presence of analytes to determine if analytes would 
be falsely identified. No interference was observed from internal standard assessment. 
Interference of other compounds was chosen based off drugs commonly encountered in 
forensic and clinical laboratories. In this case, clonazepam, diazepam, (+)methadone, 
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morphine, fentanyl, cocaine, amphetamine, 3,4-methylenedioxymethamphetamine 
(MDMA), 25I-NBOMe, and PCP were chosen for this particular study. To ensure no false 
positive identifications would arise, these compounds were tested at exceedingly high 
concentrations (2000 ng/mL). It can be concluded that there are no interferences with other 
commonly encountered substances.  
  
7. Conclusion 
7.1 Summary of Findings 
As shown by all the results of this study, an analytical method was developed and 
validated for the identification and quantification of 17 synthetic cannabinoids in human 
whole blood.. The method was developed with a total run time of 8.013 minutes and 
compounds eluting within 3.8 to 5.8 minutes. The calibration models in this method 
exhibited an R2 value of > 0.98 with a weighting factor of 1/x for all analytes. A linear 
dynamic range was established from 0.5 ng/mL to 25 ng/mL for all compounds, except for 
APP-PICA and NM2201, which were all quantifiable at lower levels (0.1 ng/mL). Percent 
recovery ranged from 54.92 to 83.36% with the developed SLE method. Bias and precision 
were assessed at 1, 3, 7, and 20 ng/mL for all analytes, except for MO-CHMINACA. All 
analytes were calculated within ±20% accuracy and ±20% CV. Carryover was not observed 
in this method, with the highest calibration concentration of 25 ng/mL. Ionization 
suppression and enhancement was observed in blood matrix from a range of -4.47 to 
76.67%. Matrix effect was determined to be insignificant in this method. Stable isotopic 
analysis of deuterated internal standards showed no sign of interference with analytes of 
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interest. Lastly, one analyte, ADB-PINACA was observed from analysis of other 
commonly encountered drugs. Further analysis of each of the common drugs showed three 
drugs (MDMA, 25I-NBOMe, and PCP) to falsely identify ADB-PINACA.  
 
7.2 Significance of Findings 
Because of the rapid growth and emergence of synthetic cannabinoids, updated 
analytical methods for the detection of these compounds are sorely needed. The recent 
emergence and the lack of published materials for these compounds have also made it 
difficult to establish appropriate levels of identification in biological specimens. As new 
designer drugs continue to flood the market, more analytical methods need to be developed 
and updated. Therefore, it is imperative that lawmakers and scientists are constantly up-to-
date with these emerging novel psychoactive substances.  
 This method has demonstrated the sensitivity, reliability, and robust capabilities of 
detecting synthetic cannabinoids in human whole blood. The results of this study and its 
fully validated parameters allow it to be adopted and used for identification and 
quantification in forensic and clinical casework.  
 
8. Future Studies 
8.1 Method Expansion 
As new synthetic cannabinoids emerge, it may be necessary to reevaluate or even 
expand the method to include more synthetic cannabinoids. Metabolites and other 
biomarkers are also important to consider and incorporate in this method. In addition, this 
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method should be expanded to test for synthetic cannabinoids in other biological matrices 
(e.g., urine, saliva, plasma, etc.).   
 
8.2 Stability Studies 
 
Other avenues to consider with future studies include long-term stability studies. 
Many testing labs may store specimens for long-term storage before initial screening or 
even re-testing. Therefore, stability of these compounds needs to be assessed in long-term 
storage in various conditions such as room temperature, refrigerator (1-10oC) and freezer 
(-20 oC) conditions. Analytes should be prepared in the appropriate matrix and stored and 
tested at various time points to determine the level of degradation that these compounds 
can undergo. Another stability study that may need to be considered is also freeze-thaw 
cycles. These studies will help scientists better understand the properties and characteristics 
of these compounds.  
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APPENDIX A:  LIMIT OF QUANTITATION CHROMATOGRAPHIC DATA  
 
Figure A: 0.5 ng/mL Sample of All Analytes in Blood 
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APPENDIX B: CARRYOVER STUDY CHROMATOGRAPHIC DATA  
 
Figure B1: 25 ng/mL Sample of All Analytes in Blood. Complete chromatographic 
separation of all analytes. 
 
 
Figure B2:  Double Blank (Blood Matrix) Following 25 ng/mL Sample in Blood.    
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APPENDIX C: MATRIX EFFECT STUDY CHROMATOGRAPHIC DATA 
 
Figure C1: Double Blank from Blood Matrix Lot 1. Slight signal intensity is present for 
JWH-210 with associated mass ions 336.3/121.2 (Q1/Q3). However, the average signal 
area for JWH-210 was calculated to be less than the LOD.  
 
 
 
 
Figure C2: Double Blank from Blood Matrix Lot 2. Slight signal intensity is present for 
JWH-210 with associated mass ions 336.3/121.2 (Q1/Q3). However, the average signal 
area for JWH-210 was calculated to be less than the LOD.  
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Figure C3: Double Blank from Blood Matrix Lot 3. No interference present in blank 
matrix. 
 
 
 
Figure C4: Double Blank from Blood Matrix Lot 4. Slight signal intensity is present for 
JWH-210 but the associated mass ions do not indicate confirmation. However, the average 
signal area for JWH-210 was calculated to be less than the LOD.  
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Figure C5: Double Blank from Blood Matrix Lot 5. Slight signal intensity is present for 
RCS-8 with associated mass ions 376.2/121.3 (Q1/Q3). However, the average signal area 
for RCS-8 was calculated to be less than the LOD.  
 
 
Figure C6: Double Blank from Blood Matrix Lot 6. Slight signal intensity is present for 
RCS-8 with associated mass ions 376.2/121.3 (Q1/Q3). However, the average signal area 
for RCS-8 was calculated to be less than the LOD.  
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Figure C7: Double Blank from Blood Matrix Lot 7. No interferences present in blank 
matrix.  
 
 
 
Figure C8: Double Blank from Blood Matrix Lot 8. Slight signal intensity is present for 
JWH-210 with associated mass ions 336.3/121.2 (Q1/Q3). However, the average signal 
area for JWH-210 was calculated to be less than the LOD.  
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Figure C9: Double Blank from Blood Matrix Lot 9. No interferences present in blank 
matrix. 
 
 
 
Figure C10: Double Blank from Blood Matrix Lot 10. No interferences present in blank 
matrix. 
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APPENDIX D: IONIZATION SUPPRESSION AND ENHANCEMENT & MATRIX 
RECOVERY CHROMATOGRAPHIC DATA 
 
 
Figure D1: 0.5 ng/mL Neat Sample of All Analytes. 
 
 
Figure D2: 15 ng/mL Neat Sample of All Analytes. 
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Figure D3: 0.5 ng/mL Post-Extracted Samples of All Analytes.  
 
 
Figure D4: 15 ng/mL Post-Extracted Samples of All Analytes.  
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Figure D5: 0.5 ng/mL Pre-Extracted Samples of All Analytes. 
 
 
Figure D6: 15 ng/mL Pre-Extracted Samples of All Analytes. 
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